[[1, [[[74.0, 53.0, 92, 16], "materials"], [[35.0, 103.0, 25, 10], "Article"], [[36.0, 116.0, 424, 20], "Bio\ufb01lm Formation on Dental Implant Biomaterials by"], [[35.0, 135.0, 459, 20], "Staphylococcus aureus Strains Isolated from Patients with"], [[35.0, 154.0, 122, 20], "Cystic Fibrosis"], [[35.0, 188.0, 380, 14], "Anna Minkiewicz-Zochniak 1 , Sylwia Jarzynka 1 , Agnieszka Iwan\u00b4 ska 2 , Kamila Strom 1 ,"], [[36.0, 201.0, 452, 14], "Bart\u0142omiej Iwan\u00b4 czyk 3, Marta Bartel 4, Maciej Mazur 4, Anna Pietruczuk-Padzik 5 , Ma\u0142gorzata Konieczna 1,"], [[36.0, 213.0, 234, 14], "Ewa Augustynowicz-Kopec\u00b4 2 and Gabriela Ole\u02dbdzka 1,*"], [[35.0, 380.0, 92, 7], "Citation: Minkiewicz-Zochniak, A.;"], [[35.0, 392.0, 101, 7], "Jarzynka, S.; Iwan\u00b4 ska, A.; Strom, K.;"], [[35.0, 404.0, 98, 7], "Iwan\u00b4 czyk, B.; Bartel, M.; Mazur, M.;"], [[35.0, 416.0, 100, 7], "Pietruczuk-Padzik, A.; Konieczna, M.;"], [[35.0, 427.0, 86, 7], "Augustynowicz-Kopec\u00b4, E.; et al."], [[35.0, 439.0, 95, 7], "Bio\ufb01lm Formation on Dental Implant"], [[35.0, 451.0, 105, 7], "Biomaterials by Staphylococcus aureus"], [[35.0, 463.0, 91, 7], "Strains Isolated from Patients with"], [[35.0, 475.0, 93, 7], "Cystic Fibrosis. Materials 2021, 14,"], [[35.0, 487.0, 78, 7], "2030. https://doi.org/10.3390/"], [[35.0, 499.0, 35, 7], "ma14082030"], [[35.0, 523.0, 92, 7], "Academic Editor: Lucio Montanaro"], [[35.0, 547.0, 65, 7], "Received: 6 March 2021"], [[35.0, 559.0, 63, 7], "Accepted: 15 April 2021"], [[35.0, 571.0, 65, 7], "Published: 17 April 2021"], [[35.0, 596.0, 102, 7], "Publisher\u2019s Note: MDPI stays neutral"], [[35.0, 608.0, 96, 7], "with regard to jurisdictional claims in"], [[35.0, 620.0, 98, 7], "published maps and institutional af\ufb01l-"], [[35.0, 632.0, 19, 7], "iations."], [[167.0, 245.0, 325, 13], "1 Department of Medical Biology, Medical University of Warsaw, Litewska 14/16, 00-575 Warsaw, Poland;"], [[180.0, 257.0, 238, 8], "anna.minkiewicz@wum.edu.pl (A.M.-Z.); sylwia.jarzynka@wum.edu.pl (S.J.);"], [[180.0, 268.0, 238, 8], "kamila.strom@wum.edu.pl (K.S.); malgorzata.konieczna@wum.edu.pl (M.K.)"], [[167.0, 277.0, 317, 13], "2 Department of Microbiology, National Tuberculosis and Lung Diseases Research Institute, P\u0142ocka 26,"], [[180.0, 289.0, 276, 8], "01-138 Warsaw, Poland; a.iwanska@igichp.edu.pl (A.I.); e.kopec@igichp.edu.pl (E.A.-K.)"], [[167.0, 298.0, 271, 13], "3 The Chair and Department of Oral Surgery, Medical University of Lublin, Karmelicka 7,"], [[180.0, 311.0, 155, 8], "20-081 Lublin, Poland; dent.iwanczyk@gmail.com"], [[167.0, 320.0, 268, 13], "4 Department of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland;"], [[180.0, 332.0, 207, 8], "mbartel@chem.uw.edu.pl (M.B.); mmazur@chem.uw.edu.pl (M.M.)"], [[167.0, 341.0, 325, 13], "5 Department of Pharmaceutical Microbiology, Centre for Preclinical Research and Technology, Faculty of"], [[180.0, 354.0, 248, 8], "Pharmacy, Medical University of Warsaw, Banacha 1B, 02-097 Warsaw, Poland;"], [[180.0, 364.0, 115, 8], "anna.pietruczuk-padzik@wum.edu.pl"], [[166.0, 375.0, 154, 8], "* Correspondence: gabriela.oledzka@wum.edu.pl"], [[166.0, 400.0, 349, 9], "Abstract: Implants made of ceramic and metallic elements, which are used in dentistry, may either"], [[166.0, 413.0, 334, 9], "promote or hinder the colonization and adhesion of bacteria to the surface of the biomaterial to"], [[167.0, 426.0, 337, 9], "varying degrees. The increased interest in the use of dental implants, especially in patients with"], [[167.0, 439.0, 358, 9], "chronic systemic diseases such as cystic \ufb01brosis (CF), is caused by an increase in disease complica-"], [[167.0, 452.0, 340, 9], "tions. In this study, we evaluated the differences in the in vitro bio\ufb01lm formation on the surface of"], [[167.0, 465.0, 338, 9], "biomaterials commonly used in dentistry (Ti-6Al-4V, cobalt-chromium alloy (CoCr), and zirconia)"], [[167.0, 478.0, 360, 9], "by Staphylococcus aureus isolated from patients with CF. We demonstrated that S. aureus adherence"], [[167.0, 491.0, 334, 9], "and growth depends on the type of material used and its surface topography. Weaker bacterial"], [[167.0, 504.0, 337, 9], "bio\ufb01lm formation was observed on zirconia surfaces compared to titanium and cobalt-chromium"], [[167.0, 517.0, 342, 9], "alloy surfaces. Moreover, scanning electron microscopy showed clear differences in bacterial ag-"], [[167.0, 530.0, 338, 9], "gregation, depending on the type of biomaterial used. Over the past several decades, S. aureus"], [[167.0, 543.0, 356, 9], "strains have developed several mechanisms of resistance, especially in patients on chronic antibiotic"], [[167.0, 556.0, 338, 9], "treatment such as CF. Therefore, the selection of an appropriate implant biomaterial with limited"], [[167.0, 569.0, 339, 9], "microorganism adhesion characteristics can affect the occurrence and progression of oral cavity"], [[167.0, 582.0, 229, 9], "infections, particularly in patients with chronic systemic diseases."], [[167.0, 607.0, 366, 9], "Keywords: biomaterials; Ti-6Al-4V; CoCr alloy; zirconia; bio\ufb01lm; Staphylococcus aureus; cystic \ufb01brosis;"], [[167.0, 620.0, 38, 9], "SEM; AFM"], [[35.0, 685.0, 93, 7], "Copyright: \u00a9 2021 by the authors."], [[35.0, 697.0, 95, 7], "Licensee MDPI, Basel, Switzerland."], [[35.0, 708.0, 96, 7], "This article is an open access article"], [[35.0, 720.0, 83, 7], "distributed under the terms and"], [[35.0, 732.0, 97, 7], "conditions of the Creative Commons"], [[35.0, 744.0, 93, 7], "Attribution (CC BY) license (https://"], [[35.0, 756.0, 90, 7], "creativecommons.org/licenses/by/"], [[35.0, 768.0, 14, 7], "4.0/)."], [[167.0, 668.0, 63, 10], "1. Introduction"], [[188.0, 684.0, 335, 10], "Dental implant treatment is important for the recovery process in patients with devel-"], [[167.0, 696.0, 341, 10], "opmental and acquired dental defects. Dental implants directly improve the oral cavity"], [[167.0, 709.0, 343, 10], "function and esthetics as well as a patient\u2019s speech and general well-being [1,2]. In re-"], [[167.0, 721.0, 346, 10], "cent times, medical professionals have increasingly used dental implant procedures for"], [[167.0, 734.0, 347, 10], "tooth replacement. Consequently, there has been an increase in the number of patients"], [[166.0, 746.0, 339, 10], "with systemic diseases requesting dental implants to replace their missing teeth [3,4]."], [[167.0, 759.0, 360, 10], "However, the increase in demand for dental implants is also associated with an increase in"], [[35.0, 815.0, 193, 8], "Materials 2021, 14, 2030. https://doi.org/10.3390/ma14082030"], [[403.0, 815.0, 121, 8], "https://www.mdpi.com/journal/materials"]], [841, 595]], [10, [[[36.0, 54.0, 77, 8], "Materials 2021, 14, 2030"], [[532.0, 54.0, 25, 8], "10 of 15"], [[188.0, 98.0, 347, 10], "The microscopy images demonstrated that a greater number of bacteria aggregated on"], [[167.0, 111.0, 361, 10], "CoCr alloy compared to those on Ti-6Al-4V and zirconia surfaces (Figure 4A,B). After 48 h,"], [[167.0, 123.0, 369, 10], "the biofilm formed on the surface of zirconia was more densely colonized than that on Ti-6Al-"], [[167.0, 136.0, 365, 10], "4V and CoCr alloy surfaces. The biofilm colonies on the surface of Ti-6Al-4V were observed"], [[167.0, 148.0, 344, 10], "to be more scattered and horizontally spread than on the other examined biomaterials."], [[167.0, 171.0, 58, 10], "4. Discussion"], [[188.0, 186.0, 339, 10], "Dental implant treatment with the use of selected biomaterials plays an important role"], [[167.0, 199.0, 366, 10], "in the convalescence of the oral cavity. Dental implants are regularly placed by dentists, and"], [[167.0, 211.0, 368, 10], "an increasing number of patients suffering from systemic diseases also opt for such implants"], [[167.0, 224.0, 340, 10], "to replace their missing teeth. However, it is important to understand and consider the"], [[167.0, 237.0, 367, 10], "consequences of pre-existing systemic diseases or diseases caused by chronic medications"], [[167.0, 249.0, 335, 10], "on the oral cavity. In patients with cystic \ufb01brosis, observed impaired transport of ions"], [[167.0, 262.0, 338, 10], "and water transport in exocrine ducts of the salivary glands, modifying of the physical"], [[167.0, 274.0, 336, 10], "and chemical properties of saliva, and the qualitative and quantitative composition of"], [[167.0, 287.0, 363, 10], "microbiota inhabiting the oral cavity and affecting its health condition seems signi\ufb01cant [48]."], [[167.0, 299.0, 354, 10], "Such measures would help to prevent implant failures, especially in patients with CF who"], [[167.0, 312.0, 188, 10], "receive or plan to receive an implant treatment."], [[188.0, 324.0, 351, 10], "Due to the increasing prevalence of S. aureus in infections related to dental biomaterials"], [[167.0, 337.0, 362, 10], "and their occurrence in chronic and recalcitrant infections in patients with CF, this pathogen"], [[167.0, 350.0, 359, 10], "is considered an important healthcare problem [17]. In recent years, bio\ufb01lms have increas-"], [[167.0, 362.0, 351, 10], "ingly been reported to play an important role in several human diseases and are respon-"], [[167.0, 375.0, 335, 10], "sible for numerous non-device-related chronic in\ufb02ammatory conditions, including CF"], [[167.0, 387.0, 335, 10], "and bio\ufb01lm-related in\ufb02ammation [13]. The ability of clinical strains to form a bio\ufb01lm is"], [[167.0, 400.0, 346, 10], "associated with the capacity of these organisms to survive in unfavorable conditions as"], [[166.0, 412.0, 341, 10], "well as on implanted biomaterials such as metals and ceramics [49]. Bio\ufb01lm formation"], [[167.0, 425.0, 355, 10], "by S. aureus and its attachment to medical implants made of biomaterials and host tissue"], [[166.0, 437.0, 362, 10], "plays an important role in the persistence of chronic infections. Indeed, S. aureus has been"], [[167.0, 450.0, 226, 10], "reported to be the initial colonizer of dental implants [50]."], [[188.0, 463.0, 344, 10], "The surface properties of biomaterials have determinant effects on biological behavior,"], [[167.0, 475.0, 354, 10], "and surface smoothness is of great importance in preventing the retention of microorgan-"], [[167.0, 488.0, 349, 10], "isms and bio\ufb01lm formation. The results obtained in this study showed that the surface of"], [[167.0, 500.0, 351, 10], "zirconium was smoother compared to the CoCr alloy and Ti6Al4V (Ra), which correlated"], [[167.0, 513.0, 135, 10], "to the lower bio\ufb01lm formation [51]."], [[188.0, 525.0, 326, 10], "A prior study reported that bacteria in bio\ufb01lms found in vivo engage in interspecies"], [[167.0, 538.0, 341, 10], "interactions, which may be important in the establishment of functional microbial com-"], [[167.0, 550.0, 341, 10], "munities in vitro [52]. Among the S. aureus strains isolated from sputum samples from"], [[166.0, 563.0, 344, 10], "patients diagnosed with CF, only 9% were unable to produce a bio\ufb01lm in vitro, possibly"], [[167.0, 575.0, 360, 10], "because interspecies interactions might shape the development, structure, and functioning"], [[167.0, 588.0, 105, 10], "of these communities [53]."], [[188.0, 600.0, 335, 10], "The ability of S. aureus to attach to dental biomaterial surfaces can result in oral dis-"], [[167.0, 613.0, 361, 10], "eases, periodontal disease, and dental caries caused by this microorganism. It may have a"], [[167.0, 626.0, 346, 10], "negative impact for health and therapy, especially in individuals with immunode\ufb01ciency,"], [[167.0, 638.0, 357, 10], "chronic systemic diseases, or chronic infection [54,55]. This study compared the suscepti-"], [[167.0, 651.0, 354, 10], "bility of three implant biomaterials towards S. aureus bio\ufb01lm formation. S. aureus showed"], [[167.0, 663.0, 356, 10], "different potential for attachment to the various dental biomaterials assessed in this study."], [[166.0, 676.0, 350, 10], "The bacterial attachment was dependent on factors such as surface roughness, electro-"], [[167.0, 688.0, 354, 10], "static forces, and chemical composition of the biomaterials used. Therefore, investigation"], [[167.0, 701.0, 352, 10], "of bio\ufb01lms grown on typical dental biomaterials plays an important role in achieving long-"], [[167.0, 714.0, 357, 10], "term success in combating implant-associated infections. An ideal implant material should"], [[167.0, 726.0, 365, 10], "be biocompatible, with adequate roughness, strength, and fracture resistance, as previously"], [[167.0, 739.0, 345, 10], "reported. [56]. Over the last 15 years, various forms of metal and ceramic coating have"], [[167.0, 751.0, 353, 10], "been used in clinical practice [57]. In this study, we investigated the most common dental"], [[167.0, 764.0, 336, 10], "implant materials made from metal (titanium and CoCr alloy) and ceramic (zirconium"]], [841, 595]], [11, [[[36.0, 54.0, 77, 8], "Materials 2021, 14, 2030"], [[532.0, 54.0, 25, 8], "11 of 15"], [[167.0, 98.0, 363, 10], "oxide) with similar surface roughness. However, the correlation between surface roughness"], [[167.0, 111.0, 361, 10], "and bacterial adhesion was not the subject of our research. Hence, the results of this study"], [[167.0, 123.0, 208, 10], "cannot be linked with speci\ufb01c surface morphologies."], [[188.0, 136.0, 314, 10], "The ability of S. aureus to form bio\ufb01lms and their high in vitro af\ufb01nity to titanium"], [[167.0, 148.0, 363, 10], "surfaces [16,58] and host tissues are important factors that promote chronic peri-implant in-"], [[167.0, 161.0, 363, 10], "fections, i.e., peri-implantitis. Moreover, S. aureus has been isolated from deep peri-implant"], [[166.0, 173.0, 352, 10], "pockets, where it presented with suppuration [40,58,59]. Indeed, the most persistent and"], [[167.0, 186.0, 356, 10], "recurrent infections are predominantly due to Staphylococcus spp., which have long been"], [[167.0, 199.0, 332, 10], "considered natural components of the oral microbiome. However, depending on the"], [[167.0, 211.0, 340, 10], "evaluated population and the associated comorbidities, the role of this bacteria in oral"], [[167.0, 224.0, 369, 10], "health is still a subject of debate [60]. Staphylococcus spp. are one of the key causes of peri-"], [[167.0, 236.0, 340, 10], "implant infections, and these ultimately lead to implant failure. However, no signi\ufb01cant"], [[167.0, 249.0, 357, 10], "relationship between Staphylococcus infection and chronic periodontitis has been demon-"], [[167.0, 261.0, 73, 10], "strated [40,58,59]."], [[188.0, 274.0, 323, 10], "Our in vitro study evaluated the differences in bio\ufb01lm formation on the surfaces of"], [[167.0, 286.0, 356, 10], "three commercially available biomaterials commonly used in dentistry (Ti-6Al-4V, CoCr al-"], [[167.0, 299.0, 355, 10], "loy, and zirconia), which is a limitation of the study. We report that S. aureus isolated from"], [[166.0, 312.0, 362, 10], "patients with CF can be reproducibly cultured on the surface of dental implant biomaterials."], [[166.0, 324.0, 354, 10], "We also found that S. aureus adherence and growth depends on the type of material and"], [[167.0, 337.0, 350, 10], "its surface topography. To ensure reproducibility, all evaluated biomaterial samples were"], [[167.0, 349.0, 344, 10], "appropriately prepared, and their surfaces were identically polished to high gloss using"], [[167.0, 362.0, 366, 10], "silicon carbide paper. Baseline SEM scans showed smooth surfaces, with only a small num-"], [[167.0, 374.0, 355, 10], "ber of shallow, homogeneous scratches that were a result of polishing. Prior studies have"], [[167.0, 387.0, 351, 10], "demonstrated that increased implant porosity and roughness may facilitate the adhesion"], [[167.0, 399.0, 360, 10], "of microorganisms to the implant surface [46,61,62]. Therefore, any part of the implant that"], [[167.0, 412.0, 292, 10], "is exposed to the oral cavity must be smooth to prevent plaque formation."], [[188.0, 425.0, 347, 10], "Bonsaglia et al. [63] have reported that enhanced bacterial adhesion and bio\ufb01lm forma-"], [[167.0, 437.0, 357, 10], "tion occurred on the surface of hydrophilic materials, including CoCr, when compared with"], [[167.0, 450.0, 362, 10], "hydrophobic materials, such as zirconia and titanium. Similarly, Jung-Su et al. [64] reported"], [[167.0, 462.0, 360, 10], "that S. aureus cells attached more easily to hydrophilic surfaces than to hydrophobic ones."], [[166.0, 475.0, 351, 10], "The SEM images obtained in our study also showed clear differences in bacterial aggre-"], [[167.0, 487.0, 347, 10], "gation, with the CoCr alloy exhibiting increased bacterial aggregation and more uniform"], [[167.0, 500.0, 338, 10], "bio\ufb01lm formation than Ti-6Al-4V and zirconia, which showed less cell-to-cell cohesion"], [[166.0, 512.0, 336, 10], "within the bio\ufb01lm. The Ti-6Al-4V alloy surface showed more bacterial dispersal and a"], [[166.0, 525.0, 349, 10], "wider spread of bacterial growth than the surface of other biomaterials. A previous study"], [[167.0, 538.0, 353, 10], "had reported similar observations with fewer bacteria found attached to zirconia surfaces"], [[167.0, 550.0, 141, 10], "compared to titanium surfaces [65]."], [[188.0, 563.0, 348, 10], "S. aureus bio\ufb01lms formed on the CoCr alloy surface in our study were more aggregated"], [[167.0, 575.0, 348, 10], "than those formed on Ti-6Al-4V and zirconia (Figure 3A(a,b)). Similarly, Leonhardt et al."], [[167.0, 588.0, 351, 10], "have reported lower bacterial adherence and density on titanium alloys [66]. We showed"], [[167.0, 600.0, 352, 10], "greater dispersion of the bacterial cells on titanium alloy than on zirconia and CoCr alloy."], [[166.0, 613.0, 346, 10], "After culturing for 48 h, the bio\ufb01lm on zirconia was more tightly colonized than those on"], [[166.0, 625.0, 347, 10], "Ti-6Al-4V and CoCr alloys. The uneven colonization of abiotic surfaces observed in this"], [[167.0, 638.0, 185, 10], "study is not uncommon for bacteria in bio\ufb01lms."], [[188.0, 651.0, 336, 10], "Our \ufb01ndings suggest a more abundant bio\ufb01lm formation on CoCr alloy than on either"], [[167.0, 663.0, 337, 10], "titanium or zirconia surfaces, which is consistent with the results of a prior study [67]."], [[166.0, 676.0, 334, 10], "The in vitro studies on bacterial adhesion to various titanium and zirconium surfaces"], [[167.0, 688.0, 367, 10], "conducted by Rimondini et al. [65] and Gr\u00f6ssner-Schreiber et al. [61] showed similar results,"], [[166.0, 701.0, 332, 10], "with considerably lower bacterial density found on zirconium than titanium surfaces."], [[167.0, 713.0, 341, 10], "Scaraono et al. [68] also observed lower bacterial density fewer bacteria on zirconium"], [[167.0, 726.0, 364, 10], "oxide surfaces during the phase of adhesion. However, it has been suggested that bacterial"], [[167.0, 738.0, 362, 10], "density was due to the surface characteristics and electrical conductivity of zirconium oxide"], [[167.0, 751.0, 350, 10], "\ufb01lms. Moreover, several reports emphasized that due to their surface properties zirconia"], [[167.0, 763.0, 336, 10], "and zirconium nitrate can inhibit dental plaque formation on the implant and adjacent"]], [841, 595]], [12, [[[36.0, 54.0, 77, 8], "Materials 2021, 14, 2030"], [[532.0, 54.0, 25, 8], "12 of 15"], [[167.0, 98.0, 353, 10], "tissues, which may play an important role in soft-tissue healing and implant success [69]."], [[167.0, 111.0, 342, 10], "More importantly, these biomaterials also help avoid peri-implant bone resorption [69]."], [[167.0, 123.0, 340, 10], "On the other hand, Lima et al. [70] and Al-Ahmad et al. [66] reported that titanium and"], [[167.0, 136.0, 334, 10], "zirconia surfaces showed similar biological properties in terms of protein adsorption,"], [[167.0, 148.0, 193, 10], "bio\ufb01lm composition, and bacterial adhesiveness."], [[188.0, 161.0, 321, 10], "In summary, our study indicated that zirconia is a better biomaterial for dental im-"], [[166.0, 173.0, 346, 10], "plants from a microbiological perspective, since less bio\ufb01lm formation was observed on"], [[167.0, 186.0, 333, 10], "zirconia than on either CoCr alloy or titanium surfaces. A great number of reports on"], [[167.0, 199.0, 345, 10], "zirconia, demonstrating its lower potential for bacterial adhesion, has contributed to the"], [[167.0, 211.0, 335, 10], "increasing popularity of this biomaterial in orthopedics, in dentistry use for root canal"], [[166.0, 224.0, 358, 10], "posts, for prosthetic abutment, and in contemporary restorative dentistry [71]. Zirconia has"], [[167.0, 236.0, 340, 10], "been introduced in implant dentistry as an alternative to titanium, mainly due to its es-"], [[167.0, 249.0, 351, 10], "thetic properties; the colour of natural teeth, absence of peri-implant tissue discoloration,"], [[167.0, 261.0, 363, 10], "and no visible metal abutments. Based on a three-year analysis, Balmer et al. [72] provided"], [[167.0, 274.0, 339, 10], "an additional reason for the preference for zirconia implants by patients. They argued"], [[167.0, 286.0, 352, 10], "that metals, such as titanium, undergo corrosion in the oral cavity due to electrochemical"], [[167.0, 299.0, 355, 10], "redox reactions, and this may cause hypersensitivity responses, as evidenced by the low,"], [[167.0, 312.0, 310, 10], "but signi\ufb01cant, proportion of dental implant patients (0.6%) allergic to titanium."], [[188.0, 324.0, 343, 10], "In addition to the above factors, the potential for good osteointegration is of the utmost"], [[167.0, 337.0, 348, 10], "importance when selecting dental implants for patients in whom the risk of in\ufb02ammation"], [[167.0, 349.0, 339, 10], "must be minimized due to their comorbidities. In patients with CF, the respiratory tract"], [[167.0, 362.0, 351, 10], "is profusely colonized by various bacteria, whose pro\ufb01le depends on both autogenic and"], [[167.0, 374.0, 335, 10], "allogenic factors. However, despite the scarcity of reports on patients with CF on the"], [[167.0, 387.0, 363, 10], "subject, S. aureus and Pseudomonas aeruginosa are found to be the predominant species,"], [[167.0, 399.0, 362, 10], "especially in adults [72]. These pathogens are also the most common causes of respiratory"], [[167.0, 412.0, 339, 10], "infections in patients with CF [73]. Over time, S. aureus strains have developed many"], [[167.0, 425.0, 360, 10], "mechanisms of resistance [74]. The intrinsic and mutation-mediated bacterial resistance to"], [[167.0, 437.0, 354, 10], "antimicrobial agents in conjunction with the lack of alternative effective treatment poses a"], [[167.0, 450.0, 355, 10], "challenge in treating infections. Studies on the oral cavity microbiome have demonstrated"], [[167.0, 462.0, 343, 10], "an increased resistance to both the immune mechanisms of the host and antimicrobial"], [[167.0, 475.0, 333, 10], "treatment, which may result in more severe and persistent infections in patients and"], [[167.0, 487.0, 346, 10], "contribute to the spread of resistant pathogens, thus increasing the risk on the patient\u2019s"], [[167.0, 500.0, 340, 10], "health. Therefore, the development or selection of an appropriate implant biomaterial,"], [[166.0, 512.0, 351, 10], "with limited early microorganism adhesion, could limit the occurrence and progression of"], [[167.0, 525.0, 208, 10], "oral cavity infections, particularly in patients with CF."], [[188.0, 538.0, 329, 10], "In order to lower the risk of bacteria from developing resistance, it is also advisable"], [[167.0, 550.0, 345, 10], "to limit the use of antiseptic and antibiotic treatments in the initial stages of peri-implant"], [[167.0, 563.0, 356, 10], "infections in patients with CF. There is a need for further studies on non-invasive methods"], [[167.0, 575.0, 354, 10], "of cleaning dental implants and other elements used in tooth replacement reconstruction,"], [[166.0, 588.0, 342, 10], "with a particular focus on their impact on the surface and structure of biomaterials and"], [[167.0, 600.0, 196, 10], "their potential use in preventing bio\ufb01lm formation."], [[167.0, 623.0, 64, 10], "5. Conclusions"], [[188.0, 638.0, 335, 10], "Within the limitations of this study, the following conclusions were drawn: in the case"], [[167.0, 651.0, 362, 10], "of S. aureus bio\ufb01lms, the number of bacterial cells and the density of the bio\ufb01lm on zirconia"], [[166.0, 663.0, 345, 10], "was lower than that observed with Ti-6Al-4V and CoCr alloys. We further conclude that"], [[167.0, 676.0, 354, 10], "an important factor in the long-term success of implants is the selection of an appropriate"], [[167.0, 688.0, 333, 10], "biomaterial for the implant. In summary, through our in vitro studies, we have shown"], [[167.0, 701.0, 358, 10], "that there is a signi\ufb01cant correlation between the dental biomaterials used and the amount"], [[167.0, 713.0, 349, 10], "of clinical S. aureus strains adhering to their surface and their ability to form a bio\ufb01lm on"], [[167.0, 726.0, 357, 10], "their surface. Therefore, in clinical settings, implants with zirconia should be considered in"], [[166.0, 739.0, 348, 10], "patients with chronic infections, such as CF. Furthermore, long-term randomized clinical"], [[167.0, 751.0, 339, 10], "and microbiological studies should be conducted in the future to determine the in vivo"], [[167.0, 764.0, 294, 10], "bene\ufb01ts of zirconia in combating and preventing chronic bio\ufb01lm infections."]], [841, 595]], [13, [[[36.0, 54.0, 77, 8], "Materials 2021, 14, 2030"], [[532.0, 54.0, 25, 8], "13 of 15"], [[166.0, 99.0, 353, 9], "Author Contributions: Conceptualization: A.M.-Z., S.J., G.O., E.A.-K., M.M. and B.I.; Methodology:"], [[166.0, 111.0, 349, 9], "A.M.-Z., S.J., G.O. and B.I.; Validation: A.M.-Z.; A.P.-P. and S.J.; Formal Analysis: A.M.-Z., S.J. and"], [[167.0, 122.0, 353, 9], "G.O.; Investigation: A.M.-Z., S.J., K.S., A.I., M.B., M.M. and M.K.; Resources: A.M.-Z., S.J., B.I., A.I.,"], [[167.0, 134.0, 333, 9], "E.A.-K., M.B. and M.M; Data Curation: A.M.-Z., S.J., G.O.; Writing\u2014Original Draft Preparation:"], [[166.0, 146.0, 348, 9], "A.M.-Z. and S.J.; Writing\u2014Review & Editing: A.M.-Z., S.J., G.O. and A.P.-P.; Visualization: A.M.-Z.,"], [[167.0, 157.0, 352, 9], "S.J., M.B. and M.M.; Supervision: A.M.-Z., S.J., E.A.-K., M.M., B.I. and G.O.; Project Administration:"], [[167.0, 169.0, 335, 9], "G.O. and A.M.-Z.; All authors have read and agreed to the published version of the manuscript."], [[167.0, 187.0, 190, 9], "Funding: This research received no external funding."], [[167.0, 205.0, 199, 9], "Institutional Review Board Statement: Not applicable."], [[167.0, 222.0, 167, 9], "Informed Consent Statement: Not applicable."], [[167.0, 240.0, 160, 9], "Data Availability Statement: Not applicable."], [[167.0, 258.0, 229, 9], "Con\ufb02icts of Interest: The authors declare no con\ufb02ict of interest."], [[36.0, 279.0, 49, 10], "References"], [[36.0, 294.0, 451, 9], "1. Dewan, S.; Khullar, A.; Sehgal, M.; Arora, A. Implant failures: A broader perspective. J. Dent. Implants 2015, 5, 53. [CrossRef]"], [[36.0, 306.0, 261, 9], "2. Missika, P.; Bessade, J. Dental implants. Rev. Prat. 2018, 68, 827\u2013830."], [[36.0, 317.0, 450, 9], "3. Gheorghiu, I.M.; Stoian, I.M. Implant surgery in healthy compromised patients-review of literature. J. Med. Life 2014, 7, 7\u201310."], [[57.0, 329.0, 34, 9], "[PubMed]"], [[36.0, 341.0, 456, 9], "4. Manor, Y.; Simon, R.; Haim, D.; Garfunkel, A.; Moses, O. Dental implants in medically complex patients\u2014A retrospective study."], [[57.0, 352.0, 177, 9], "Clin. Oral Investig. 2016, 21, 701\u2013708. [CrossRef]"], [[36.0, 363.0, 457, 9], "5. Liaw, K.; Del\ufb01ni, R.H.; Abrahams, J.J. Dental implant complications. Semin. Ultrasound CT MRI 2015, 36, 427\u2013433. [CrossRef]"], [[57.0, 375.0, 34, 9], "[PubMed]"], [[36.0, 386.0, 478, 9], "6. Bjarnsholt, T. The role of bacterial bio\ufb01lms in chronic infections. Acta Pathol. Microbiol. Immunol. Scand. 2013, 121, 1\u201358. [CrossRef]"], [[57.0, 398.0, 34, 9], "[PubMed]"], [[36.0, 409.0, 296, 9], "7. Otto, M. Staphylococcal Bio\ufb01lms. Microbiol. Spectr. 2019, 6, 699\u2013711. [CrossRef]"], [[35.0, 421.0, 452, 9], "8. Roman\u00f2, C.L.; Scarponi, S.; Gallazzi, E.; Roman\u00f2, D.; Drago, L. Antibacterial coating of implants in orthopaedics and trauma:"], [[57.0, 432.0, 352, 9], "A classi\ufb01cation proposal in an evolving panorama. J. Orthop. Surg. Res. 2015, 10, 1\u201311. [CrossRef]"], [[35.0, 444.0, 443, 9], "9. Shah, S.R.; Tatara, A.M.; D\u2019Souza, R.N.; Mikos, A.G.; Kasper, F.K. Evolving strategies for preventing bio\ufb01lm on implantable"], [[57.0, 456.0, 194, 9], "materials. Mater. Today 2013, 16, 177\u2013182. [CrossRef]"], [[36.0, 467.0, 437, 9], "10. H\u00f8iby, N. Understanding bacterial bio\ufb01lms in patients with cystic \ufb01brosis: Current and innovative approaches to potential"], [[57.0, 479.0, 197, 9], "therapies. J. Cyst. Fibros. 2002, 1, 249\u2013254. [CrossRef]"], [[35.0, 490.0, 354, 9], "11. Del Pozo, J.L. Bio\ufb01lm-related disease. Expert Rev. Anti-Infect. Ther. 2018, 16, 51\u201365. [CrossRef]"], [[36.0, 502.0, 482, 9], "12. Dewhirst, F.E.; Chen, T.; Izard, J.; Paster, B.J.; Tanner, A.C.R.; Yu, W.-H.; Lakshmanan, A.; Wade, W.G. The human oral microbiome."], [[57.0, 513.0, 166, 9], "J. Bacteriol. 2010, 192, 5002\u20135017. [CrossRef]"], [[35.0, 525.0, 467, 9], "13. Ehrlich, G.D.; Hu, F.Z.; Post, J.C. Role for bio\ufb01lms in infectious disease. In Microbial Bio\ufb01lms; American Society for Microbiology:"], [[57.0, 536.0, 152, 9], "Washington, DC, USA, 2004; pp. 332\u2013358."], [[36.0, 548.0, 455, 9], "14. H\u00f8iby, N.; Ciofu, O.; Bjarnsholt, T. Pseudomonas aeruginosa bio\ufb01lms in cystic \ufb01brosis. Future Microbiol. 2010, 5, 1663\u20131674."], [[57.0, 559.0, 38, 9], "[CrossRef]"], [[36.0, 571.0, 460, 9], "15. Preethanath, R.S.; AlNahas, N.W.; Bin Huraib, S.M.; Al-Balbeesi, H.O.; Almalik, N.K.; Dalati, M.H.N.; Divakar, D.D. Microbiome"], [[57.0, 582.0, 316, 9], "of dental implants and its clinical aspect. Microbiol. Pathog. 2017, 106, 20\u201324. [CrossRef]"], [[35.0, 594.0, 477, 9], "16. Heitz-Mayfield, L.J.A.; Lang, N.P. Comparative biology of chronic and aggressive periodontitis vs. peri-implantitis. Periodontol. 2000"], [[57.0, 605.0, 145, 9], "2010, 53, 167\u2013181. [CrossRef] [PubMed]"], [[36.0, 617.0, 485, 9], "17. Gilbert, P.; Allison, D.G.; McBain, A.J. Biofilms in vitro and in vivo: Do singular mechanisms imply cross-resistance? J. Appl. Microbiol."], [[57.0, 628.0, 104, 9], "2002, 92, 98\u2013110. [CrossRef]"], [[36.0, 640.0, 450, 9], "18. Oliveira, W.; Silva, P.; Silva, R.; Silva, G.; Machado, G.; Coelho, L.; Correia, M. Staphylococcus aureus and Staphylococcus"], [[57.0, 651.0, 287, 9], "epidermidis infections on implants. J. Hosp. Infect. 2018, 98, 111\u2013117. [CrossRef]"], [[36.0, 663.0, 465, 9], "19. Esposito, S.; Pennoni, G.; Mencarini, V.; Palladino, N.; Peccini, L.; Principi, N. Antimicrobial treatment of Staphylococcus aureus"], [[57.0, 674.0, 301, 9], "in patients with cystic \ufb01brosis. Front. Pharmacol. 2019, 10, 849. [CrossRef] [PubMed]"], [[35.0, 686.0, 460, 9], "20. Goss, C.H.; Muhlebach, M.S. Review: Staphylococcus aureus and MRSA in cystic \ufb01brosis. J. Cyst. Fibros. 2011, 10, 298\u2013306."], [[57.0, 697.0, 74, 9], "[CrossRef] [PubMed]"], [[36.0, 709.0, 465, 9], "21. Weiner, L.M.; Webb, A.K.; Limbago, B.; Dudeck, M.A.; Patel, J.; Kallen, A.J.; Edwards, J.R.; Sievert, D.M. Antimicrobial-resistant"], [[57.0, 720.0, 454, 9], "pathogens associated with healthcare-associated infections: Summary of data reported to the national healthcare safety network"], [[57.0, 732.0, 452, 9], "at the centers for disease control and prevention, 2011\u20132014. Infect. Control Hosp. Epidemiol. 2016, 37, 1288\u20131301. [CrossRef]"], [[57.0, 743.0, 34, 9], "[PubMed]"], [[36.0, 755.0, 482, 9], "22. Woo, S.-G.; Lee, S.-Y.; Lim, K.-H.; Ha, E.-J.; Eom, Y.-B. Activity of novel inhibitors of Staphylococcus aureus bio\ufb01lms. Folia Microbiol."], [[57.0, 766.0, 109, 9], "2017, 62, 157\u2013167. [CrossRef]"]], [841, 595]], [14, [[[36.0, 54.0, 77, 8], "Materials 2021, 14, 2030"], [[532.0, 54.0, 25, 8], "14 of 15"], [[36.0, 99.0, 458, 9], "23. Moormeier, D.E.; Bayles, K.W. Staphylococcus aureus bio\ufb01lm: A complex developmental organism. Mol. Microbiol. 2017, 104,"], [[57.0, 110.0, 110, 9], "365\u2013376. [CrossRef] [PubMed]"], [[36.0, 122.0, 473, 9], "24. Garrett, T.R.; Bhakoo, M.; Zhang, Z. Bacterial adhesion and bio\ufb01lms on surfaces. Prog. Nat. Sci. 2008, 18, 1049\u20131056. [CrossRef]"], [[36.0, 133.0, 474, 9], "25. Foster, T.J.; Geoghegan, J.A.; Ganesh, V.K.; H\u00f6\u00f6k, M. Adhesion, invasion and evasion: The many functions of the surface proteins"], [[57.0, 145.0, 294, 9], "of Staphylococcus aureus. Nat. Rev. Genet. 2014, 12, 49\u201362. [CrossRef] [PubMed]"], [[36.0, 156.0, 453, 9], "26. Nguyen, H.T.; Nguyen, T.H.; Otto, M. The staphylococcal exopolysaccharide PIA\u2014Biosynthesis and role in bio\ufb01lm formation,"], [[57.0, 168.0, 359, 9], "colonization, and infection. Comput. Struct. Biotechnol. J. 2020, 18, 3324\u20133334. [CrossRef] [PubMed]"], [[36.0, 179.0, 455, 9], "27. Teughels, W.; Van Assche, N.; Sliepen, I.; Quirynen, M. Effect of material characteristics and/or surface topography on bio\ufb01lm"], [[57.0, 191.0, 237, 9], "development. Clin. Oral Implants Res. 2006, 17, 68\u201381. [CrossRef]"], [[36.0, 202.0, 458, 9], "28. B\u00fcttner, H.; Mack, D.; Rohde, H. Structural basis of Staphylococcus epidermidis bio\ufb01lm formation: Mechanisms and molecular"], [[57.0, 214.0, 187, 9], "interactions. Front. Cell Infect. Microbiol. 2015, 5, 14."], [[36.0, 225.0, 447, 9], "29. Moormeier, D.E.; Bose, J.L.; Horswill, A.R.; Bayles, K.W. Temporal and stochastic control of Staphylococcus aureus bio\ufb01lm"], [[57.0, 237.0, 171, 9], "development. mBio 2014, 5, e01341. [CrossRef]"], [[36.0, 248.0, 464, 9], "30. Izano, E.A.; Amarante, M.A.; Kher, W.B.; Kaplan, J.B. Differential roles of poly-N-acetylglucosamine surface polysaccharide and"], [[57.0, 260.0, 463, 9], "extracellular DNA in Staphylococcus aureus and Staphylococcus epidermidis bio\ufb01lms. Appl. Environ. Microbiol. 2007, 74, 470\u2013476."], [[57.0, 271.0, 38, 9], "[CrossRef]"], [[36.0, 283.0, 462, 9], "31. Dufour, D.; Leung, V.; L\u00e9vesque, C.M. Bacterial bio\ufb01lm: Structure, function, and antimicrobial resistance. Endod. Top. 2010, 22,"], [[57.0, 294.0, 60, 9], "2\u201316. [CrossRef]"], [[36.0, 306.0, 474, 9], "32. Mah, T.-F.C.; O\u2019Toole, G.A. Mechanisms of bio\ufb01lm resistance to antimicrobial agents. Trends Microbiol. 2001, 9, 34\u201339. [CrossRef]"], [[36.0, 317.0, 413, 9], "33. Stewart, P.S.; Costerton, J.W. Antibiotic resistance of bacteria in bio\ufb01lms. Lancet 2001, 358, 135\u2013138. [CrossRef]"], [[36.0, 329.0, 464, 9], "34. Jamal, M.; Ahmad, W.; Andleeb, S.; Jalil, F.; Imran, M.; Nawaz, M.A.; Hussain, T.; Ali, M.; Ra\ufb01q, M.; Kamil, M.A. Bacterial bio\ufb01lm"], [[57.0, 340.0, 265, 9], "and associated infections. J. Chin. Med. Assoc. 2018, 81, 7\u201311. [CrossRef]"], [[35.0, 352.0, 462, 9], "35. Costerton, J.W.; Stewart, P.S.; Greenberg, E.P. Bacterial bio\ufb01lms: A common cause of persistent infections. Science 1999, 284,"], [[57.0, 364.0, 82, 9], "1318\u20131322. [CrossRef]"], [[36.0, 375.0, 479, 9], "36. Saini, M.; Singh, Y.; Arora, P.; Arora, V.; Jain, K. Implant biomaterials: A comprehensive review. World J. Clin. Cases 2015, 3, 52\u201357."], [[57.0, 387.0, 74, 9], "[CrossRef] [PubMed]"], [[36.0, 398.0, 458, 9], "37. Prakasam, M.; Locs, J.; Salma-Ancane, K.; Loca, D.; Largeteau, A.; Berzina-Cimdina, L. Biodegradable materials and metallic"], [[57.0, 409.0, 260, 9], "implants\u2014A review. J. Funct. Biomater. 2017, 8, 44. [CrossRef] [PubMed]"], [[36.0, 421.0, 466, 9], "38. Williams, D.F. Speci\ufb01cations for innovative, enabling biomaterials based on the principles of biocompatibility mechanisms. Front."], [[57.0, 432.0, 194, 9], "Bioeng. Biotechnol. 2019, 7, 255. [CrossRef] [PubMed]"], [[36.0, 444.0, 405, 9], "39. Williams, D.F. On the mechanisms of biocompatibility. Biomaterials 2008, 29, 2941\u20132953. [CrossRef] [PubMed]"], [[35.0, 456.0, 452, 9], "40. de Avila, E.D.; de Molon, R.S.; Vergani, C.E.; de Assis Mollo, F., Jr.; Salih, V. The relationship between bio\ufb01lm and physi-cal-"], [[57.0, 467.0, 436, 9], "chemical properties of implant abutment materials for successful dental implants. Materials 2014, 7, 3651\u20133662. [CrossRef]"], [[36.0, 479.0, 447, 9], "41. Holst, S.; Blatz, M.B.; Hegenbarth, E.; Wichmann, M.; Eitner, S. Prosthodontic considerations for predictable single-implant"], [[57.0, 490.0, 302, 9], "esthetics in the anterior maxilla. J. Oral Maxillofac. Surg. 2005, 63, 89\u201396. [CrossRef]"], [[36.0, 501.0, 456, 9], "42. Molin, M.K.; Karlsson, S.L. Five-year clinical prospective evaluation of zirconia-based Denzir 3-unit FPDs. Int. J. Prosthodont."], [[57.0, 513.0, 69, 9], "2008, 21, 223\u2013227."], [[36.0, 525.0, 475, 9], "43. Anderson, M.J.; Lin, Y.-C.; Gillman, A.N.; Parks, P.J.; Schlievert, P.M.; Peterson, M.L. Alpha-toxin promotes Staphylococcus aureus"], [[57.0, 536.0, 279, 9], "mucosal bio\ufb01lm formation. Front. Cell. Infect. Microbiol. 2012, 2, 64. [CrossRef]"], [[36.0, 548.0, 432, 9], "44. The European Committee on Antimicrobial Susceptibility Testing Breakpoint Tables for Interpretation of MICs and Zone"], [[57.0, 559.0, 356, 9], "Diameters. 2020 (Version 10.0). Available online: http://www.eucast.org/ (accessed on 21 July 2020)."], [[36.0, 568.0, 482, 9], "45. Stepanovic\u00b4, S.; Vukovic\u00b4, D.; Hola, V.; Di Bonaventura, G.; Djukic\u00b4, S.; C\u00b4 irkovic\u00b4, I.; Ruzicka, F. Quanti\ufb01cation of bio\ufb01lm in microtiter"], [[57.0, 582.0, 439, 9], "plates: Overview of testing conditions and practical recommendations for assessment of bio\ufb01lm production by staphylococci."], [[57.0, 594.0, 257, 9], "Acta Pathol. Microbiol. Immunol. Scand. 2007, 115, 891\u2013899. [CrossRef]"], [[36.0, 605.0, 453, 9], "46. B\u00fcrgers, R.; Gerlach, T.; Hahnel, S.; Schwarz, F.; Handel, G.; Gosau, M. In vivo and in vitro bio\ufb01lm formation on two different"], [[57.0, 617.0, 289, 9], "titanium implant surfaces. Clin. Oral Implants Res. 2010, 21, 156\u2013164. [CrossRef]"], [[36.0, 628.0, 433, 9], "47. Stepanovic, S.; Vukovic, D.; Dakic, I.; Savic, B.; Svabic-Vlahovic, M. A modi\ufb01ed microtiter-plate test for quanti\ufb01cation of"], [[57.0, 640.0, 305, 9], "staphylococcal bio\ufb01lm formation. J. Microbiol. Methods 2000, 40, 175\u2013179. [CrossRef]"], [[35.0, 651.0, 471, 9], "48. Pawlaczyk-Kamien\u00b4 ska, T.; Borysewicz-Lewicka, M.; Batura-Gabryel, H. Salivary biomarkers and oral microbial load in relation to"], [[57.0, 663.0, 344, 9], "the dental status of adults with cystic \ufb01brosis. Microorganisms 2019, 7, 692. [CrossRef] [PubMed]"], [[36.0, 674.0, 470, 9], "49. Donlan, R.M.; Costerton, J.W. Bio\ufb01lms: Survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 2002, 15,"], [[57.0, 686.0, 73, 9], "167\u2013193. [CrossRef]"], [[36.0, 697.0, 464, 9], "50. F\u00fcrst, M.M.; Salvi, G.E.; Lang, N.P.; Persson, G.R. Bacterial colonization immediately after installation on oral titanium implants."], [[57.0, 709.0, 232, 9], "Clin. Oral Implants Res. 2007, 18, 501\u2013508. [CrossRef] [PubMed]"], [[36.0, 720.0, 480, 9], "51. Sen, D.; Goller, G.; Issever, H. The effect of two polishing pastes on the surface roughness of bis-acryl composite and methacrylate-"], [[57.0, 732.0, 259, 9], "based resins. J. Prosthet. Dent. 2002, 88, 527\u2013532. [CrossRef] [PubMed]"], [[36.0, 743.0, 460, 9], "52. Diaz, P.I.; Chalmers, N.I.; Rickard, A.H.; Kong, C.; Milburn, C.L.; Palmer, R.J.; Kolenbrander, P.E. Molecular characterization of"], [[57.0, 755.0, 445, 9], "subject-speci\ufb01c oral micro\ufb02ora during initial colonization of enamel. Appl. Environ. Microbiol. 2006, 72, 2837\u20132848. [CrossRef]"]], [841, 595]], [15, [[[36.0, 54.0, 77, 8], "Materials 2021, 14, 2030"], [[532.0, 54.0, 25, 8], "15 of 15"], [[36.0, 99.0, 478, 9], "53. Giaouris, E.; Heir, E.; Desvaux, M.; H\u00e9braud, M.; M\u00f8retr\u00f8, T.; Langsrud, S.; Doulgeraki, A.; Nychas, G.-J.; Kac\u02c7\u00e1niov\u00e1, M.; Czaczyk,"], [[57.0, 110.0, 456, 9], "K.; et al. Intra- and inter-species interactions within bio\ufb01lms of important foodborne bacterial pathogens. Front. Microbiol. 2015, 6,"], [[57.0, 122.0, 56, 9], "841. [CrossRef]"], [[36.0, 133.0, 451, 9], "54. Migliorati, C.A.; Madrid, C. The interface between oral and systemic health: The need for more collaboration. Clin. Microbiol."], [[57.0, 145.0, 124, 9], "Infect. 2007, 13, 11\u201316. [CrossRef]"], [[36.0, 156.0, 453, 9], "55. Tunney, M.M.; Field, T.R.; Moriarty, T.F.; Patrick, S.; Doering, G.; Muhlebach, M.S.; Wolfgang, M.C.; Boucher, R.; Gilpin, D.F.;"], [[57.0, 168.0, 446, 9], "McDowell, A.; et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic \ufb01brosis. Am. J. Respir."], [[57.0, 179.0, 211, 9], "Crit. Care Med. 2008, 177, 995\u20131001. [CrossRef] [PubMed]"], [[36.0, 191.0, 456, 9], "56. Osman, R.B.; Swain, M.V. A critical review of dental implant materials with an emphasis on titanium versus zirconia. Materials"], [[57.0, 202.0, 105, 9], "2015, 8, 932\u2013958. [CrossRef]"], [[36.0, 214.0, 463, 9], "57. Berner, S.; Dard, M.; Gottlow, J.; Molenberg, A.; Wieland, M. Titanium-zirconium: A novel material for dental implants. Eur. Cells"], [[57.0, 225.0, 93, 9], "Mater. 2009, 17, 189\u2013205."], [[36.0, 237.0, 458, 9], "58. Harris, L.; Mead, L.; M\u00fcller-Oberl\u00e4nder, E.; Richards, R.G. Bacteria and cell cytocompatibility studies on coated medical grade"], [[57.0, 248.0, 308, 9], "titanium surfaces. J. Biomed. Mater. Res. Part A 2006, 78, 50\u201358. [CrossRef] [PubMed]"], [[35.0, 260.0, 469, 9], "59. Rams, T.E.; Feik, D.; Slots, J. Staphylococci in human periodontal diseases. Oral Microbiol. Immunol. 1990, 5, 29\u201332. [CrossRef]"], [[57.0, 271.0, 34, 9], "[PubMed]"], [[36.0, 283.0, 460, 9], "60. Renvert, S.; Lindahl, C.; Renvert, H.; Persson, G.R. Clinical and microbiological analysis of subjects treated with Br\u00e5nemark or"], [[57.0, 294.0, 357, 9], "AstraTech implants: A 7-year follow-up study. Clin. Oral Implants Res. 2008, 19, 342\u2013347. [CrossRef]"], [[36.0, 306.0, 470, 9], "61. Gr\u00f6ssner-Schreiber, B.; Teichmann, J.; Hannig, M.; D\u00f6rfer, C.; Wenderoth, D.F.; Ott, S.J. Modi\ufb01ed implant surfaces show different"], [[57.0, 317.0, 397, 9], "bio\ufb01lm compositions under in vivo conditions. Clin. Oral. Implants Res. 2009, 20, 817\u2013826. [CrossRef] [PubMed]"], [[36.0, 329.0, 471, 9], "62. Leonhardt, A.; Bergstr\u00f6m, C.; Lekholm, U. Microbiologic diagnostics at titanium implants. Clin. Implants Dent. Relat. Res. 2003, 5,"], [[57.0, 340.0, 110, 9], "226\u2013232. [CrossRef] [PubMed]"], [[36.0, 352.0, 470, 9], "63. Bonsaglia, E.C.; Silva, N.C.; J\u00fanior, A.F.; J\u00fanior, J.A.; Tsunemi, M.H.; Rall, V.L. Production of bio\ufb01lm by Listeria monocytogenes in"], [[57.0, 363.0, 290, 9], "different materials and temperatures. Food Control 2014, 35, 386\u2013391. [CrossRef]"], [[36.0, 375.0, 464, 9], "64. Lee, J.S.; Bae, Y.M.; Lee, S.Y.; Lee, S.Y. Bio\ufb01lm formation of Staphylococcus aureus on various surfaces and their resistance to"], [[57.0, 386.0, 240, 9], "chlorine sanitizer. J. Food Sci. 2015, 80, M2279\u2013M2286. [CrossRef]"], [[36.0, 398.0, 451, 9], "65. Rimondini, L.; Cerroni, L.; Carrassi, A.; Torricelli, P. Bacterial colonization of zirconia ceramic surfaces: An in vitro and in vivo"], [[57.0, 409.0, 204, 9], "study. Int. J. Oral Maxillofac. Implants 2003, 17, 793\u2013798."], [[36.0, 421.0, 462, 9], "66. Leonhardt, A.; Olsson, J.; Dahl\u00e9n, G. Bacterial colonization on titanium, hydroxyapatite, and amalgam surfaces in vivo. J. Dent."], [[57.0, 432.0, 173, 9], "Res. 1995, 74, 1607\u20131612. [CrossRef] [PubMed]"], [[36.0, 444.0, 455, 9], "67. Al-Ahmad, A.; Wiedmann-Al-Ahmad, M.; Faust, J.; B\u00e4chle, M.; Follo, M.; Wolkewitz, M.; Hannig, C.; Hellwig, E.; Carvalho, C.;"], [[57.0, 455.0, 451, 9], "Kohal, R. Bio\ufb01lm formation and composition on different implant materials in vivo. J. Biomed. Mater. Res. Part B Appl. Biomater."], [[57.0, 467.0, 145, 9], "2010, 95, 101\u2013109. [CrossRef] [PubMed]"], [[36.0, 479.0, 458, 9], "68. Scarano, A.; Piattelli, M.; Caputi, S.; Favero, G.A.; Piattelli, A. Bacterial adhesion on commercially pure titanium and zirconium"], [[57.0, 490.0, 329, 9], "oxide disks: An in vivo human study. J. Periodontol. 2004, 75, 292\u2013296. [CrossRef] [PubMed]"], [[35.0, 502.0, 471, 9], "69. Hisbergues, M.; Vendeville, S.; Vendeville, P. Zirconia: Established facts and perspectives for a biomaterial in dental implantology."], [[57.0, 513.0, 273, 9], "J. Biomed. Mater. Res. Part B Appl. Biomater. 2009, 88, 519\u2013529. [CrossRef]"], [[36.0, 525.0, 459, 9], "70. Lima, E.M.; Koo, H.; Smith, A.M.; Rosalen, P.L.; Cury, A.A. Adsorption of salivary and serum proteins, and bacterial adherence"], [[57.0, 536.0, 347, 9], "on titanium and zirconia ceramic surfaces. Clin. Oral Implants Res. 2008, 19, 780\u2013785. [CrossRef]"], [[36.0, 548.0, 448, 12], "71. Nistor, L.; Gr\u0103dinaru, M.; R\u00eec\u0103, R.; M\u0103r\u0103s, escu, P.; Stan, M.; Manolea, H.; Ionescu, A.; Moraru, I. Zirconia use in dentistry\u2014"], [[57.0, 559.0, 238, 9], "Manufacturing and properties. Curr. Health Sci. J. 2019, 45, 28\u201335."], [[35.0, 571.0, 473, 9], "72. Cox, M.J.; Allgaier, M.; Taylor, B.; Baek, M.S.; Huang, Y.J.; Daly, R.A.; Karaoz, U.; Andersen, G.L.; Brown, R.; Fujimura, K.E.; et al."], [[57.0, 582.0, 438, 9], "Airway microbiota and pathogen abundance in age-strati\ufb01ed cystic \ufb01brosis patients. PLoS ONE 2010, 5, e11044. [CrossRef]"], [[36.0, 594.0, 455, 9], "73. Fug\u00e8re, A.; S\u00e9guin, D.L.; Mitchell, G.; D\u00e9ziel, E.; Dekimpe, V.; Cantin, A.M.; Frost, E.; Malouin, F. Interspeci\ufb01c small molecule"], [[57.0, 605.0, 454, 9], "interactions between clinical isolates of Pseudomonas aeruginosa and Staphylococcus aureus from adult cystic \ufb01brosis patients."], [[57.0, 617.0, 178, 9], "PLoS ONE 2014, 9, e86705. [CrossRef] [PubMed]"], [[36.0, 628.0, 460, 9], "74. McCormack, M.; Smith, A.; Akram, A.; Jackson, M.; Robertson, D.; Edwards, G. Staphylococcus aureus and the oral cavity: An"], [[57.0, 640.0, 336, 9], "overlooked source of carriage and infection? Am. J. Infect. Control 2015, 43, 35\u201337. [CrossRef]"]], [841, 595]], [2, [[[36.0, 54.0, 77, 8], "Materials 2021, 14, 2030"], [[536.0, 54.0, 21, 8], "2 of 15"], [[167.0, 96.0, 356, 10], "complications associated with the procedure [5]. Therefore, the planning and execution of"], [[167.0, 109.0, 355, 10], "dental implant placement often requires an interdisciplinary collaboration with recognizing"], [[167.0, 122.0, 350, 10], "and determining the consequences of any ongoing systemic diseases, particularly acute"], [[167.0, 134.0, 355, 10], "and chronic infections caused by bacteria growing in structures referred to as bio\ufb01lms [6]."], [[167.0, 147.0, 354, 10], "Bio\ufb01lm is de\ufb01ned as a complex interaction of unicellular organisms, free-\ufb02oating bacterial"], [[167.0, 159.0, 342, 10], "aggregates or aggregates attached to a surface, embedded in a matrix of extracellular"], [[166.0, 172.0, 201, 10], "polymeric substances that they have produced [7]."], [[188.0, 184.0, 330, 10], "Dental plaque is a perfect example of synergism between the bacteria and the host"], [[166.0, 197.0, 332, 10], "who provide a surface for bacterial adhesion. The structure of bio\ufb01lms was also \ufb01rst"], [[167.0, 209.0, 346, 10], "described in dental plaques in the human body [6]. Based on recent reports, the bio\ufb01lm"], [[167.0, 222.0, 342, 10], "that forms on dental biomaterials is the most important risk factor leading to the devel-"], [[167.0, 234.0, 326, 10], "opment of implant-related infections. A bio\ufb01lm starts forming immediately upon the"], [[167.0, 247.0, 344, 10], "adherence of bacteria to an implant surface [8]. Chronic implant-related infections may"], [[167.0, 260.0, 340, 10], "be caused by the microenvironment created by the bio\ufb01lm, wherein the bacteria toler-"], [[167.0, 272.0, 345, 10], "ate antimicrobial drugs, over-the-counter antiseptic agents, and host immune response"], [[167.0, 285.0, 375, 10], "mechanisms [6,9\u201311]. Biomaterial-related infections, dental plaque formation, chronic wounds,"], [[166.0, 297.0, 339, 10], "periodontal disease, and pneumonia are particularly dangerous in patients with cystic"], [[167.0, 310.0, 177, 10], "\ufb01brosis (CF) and dental implants [10,12\u201314]."], [[188.0, 322.0, 338, 10], "To date, approximately 700 bacterial species that form bio\ufb01lms in the oral cavity have"], [[167.0, 335.0, 370, 10], "been described, including over 400 species capable of adhering to teeth and dental implants,"], [[167.0, 347.0, 333, 10], "forming a bio\ufb01lm on their surfaces, and growing in the gingival sulci and pockets [8]."], [[166.0, 360.0, 350, 10], "Although a bio\ufb01lm typically forms within 2 to 6 h, the conditions in the oral cavity and the"], [[166.0, 373.0, 350, 10], "presence of nutrients may decrease the time needed for bio\ufb01lm formation (both on teeth"], [[167.0, 385.0, 347, 10], "and on dental implants) to 30 min [15]. Moreover, the bio\ufb01lm composition in people with"], [[167.0, 398.0, 345, 10], "edentulous areas closely corresponds to the bacteria found in adjacent tissues [15,16]."], [[188.0, 410.0, 365, 10], "Staphylococcus aureus has been reported to be a common cause of chronic and treatment-"], [[167.0, 423.0, 331, 10], "refractory infections in many patients with dental implants, particularly among those"], [[167.0, 435.0, 351, 10], "suffering from CF [17\u201321]. Additionally, infection-related implant failure is also commonly"], [[167.0, 448.0, 355, 10], "associated with. S. aureus colonization and bio\ufb01lm formation [22], which involves multiple"], [[167.0, 460.0, 352, 10], "stages, including adherence, maturation, and dispersal of bacteria [23]. S. aureus bio\ufb01lm"], [[167.0, 473.0, 356, 10], "growth is initially due to multiple interrelated physical, chemical, and biological processes."], [[166.0, 485.0, 348, 10], "S. aureus adhesion to abiotic surfaces and eukaryotic cells occurs via cell wall proteins,"], [[166.0, 498.0, 333, 10], "which play a role in cell-to-cell cohesion, de\ufb01ned as inter-cell interactions, within the"], [[167.0, 511.0, 357, 10], "bio\ufb01lm [20,24]. The cell wall proteins are also a major virulence factor in infections associ-"], [[167.0, 523.0, 222, 10], "ated with implants made of various biomaterials [25,26]."], [[188.0, 536.0, 321, 10], "Various ceramic and metal components of dental implants may either facilitate or"], [[167.0, 548.0, 356, 10], "hinder bacterial adhesion. Bacterial colonization and bio\ufb01lm formation on biomaterials are"], [[167.0, 561.0, 348, 10], "directly associated with implant surface characteristics such as porosity, hydrophobicity,"], [[167.0, 573.0, 347, 10], "chemical composition, and shape [27]. Early stages of bacterial colonization involve the"], [[167.0, 586.0, 350, 10], "formation of a cell monolayer, followed by cell aggregation facilitated by the extracellular"], [[167.0, 599.0, 362, 10], "matrix produced, which contains various extracellular polymeric substances and extracellu-"], [[167.0, 611.0, 363, 10], "lar DNA. The presence of extracellular DNA is a key factor for the adherence of cells during"], [[166.0, 623.0, 359, 10], "S. aureus and S. epidermidis bio\ufb01lm formation [23,28\u201330]. In addition, lipopolysaccharides"], [[167.0, 636.0, 361, 10], "and exopolysaccharides also participate in bacterial cell\u2013surface interactions [31]. All these"], [[167.0, 649.0, 343, 10], "factors lead to the formation of a three-dimensional bio\ufb01lm whose structure is resistant"], [[167.0, 661.0, 341, 10], "to both environmental factors and to the neutrophils and macrophages from the host\u2019s"], [[167.0, 674.0, 362, 10], "immune system. Compared to planktonic bacteria, the bacteria that are part of a bio\ufb01lm are"], [[166.0, 686.0, 364, 10], "100\u20131000 times more resistant to antibiotics and antimicrobial agents, which may be due to"], [[167.0, 699.0, 350, 10], "the genetic, metabolic, and physical properties of bio\ufb01lms [17,18,32,33]. Planktonic cells"], [[167.0, 711.0, 345, 10], "can detach from the surface of mature bio\ufb01lm and disperse in organism to continue the"], [[167.0, 724.0, 245, 10], "cycle of bio\ufb01lm formation on other surfaces and niche [34,35]."], [[188.0, 737.0, 335, 10], "Many biomaterials are suitable for use in the human body and include both synthetic"], [[167.0, 749.0, 352, 10], "and natural materials; for example, metals (stainless steel, cobalt alloys, titanium alloys),"], [[167.0, 762.0, 346, 10], "ceramics (aluminum oxide, zirconium dioxide or zirconia, calcium phosphate), and syn-"]], [841, 595]], [3, [[[36.0, 54.0, 77, 8], "Materials 2021, 14, 2030"], [[536.0, 54.0, 21, 8], "3 of 15"], [[167.0, 98.0, 342, 10], "thetic and natural polymers [36\u201338]. The main material used for dental implants is tita-"], [[167.0, 111.0, 344, 10], "nium (Ti), which is one of the key biomaterials due to its biocompatibility, bio-inertness,"], [[167.0, 123.0, 363, 10], "tensile strength, elasticity, and corrosion resistance [38\u201340], but the aesthetic problems can"], [[167.0, 136.0, 366, 10], "be found due to the metallic color of the titanium. Therefore, dental research has focused on"], [[167.0, 148.0, 357, 10], "discovering natural tooth-colored implant material that improves the aesthetic appearance"], [[167.0, 161.0, 220, 10], "of dental implants or implant-supported bridges [41,42]."], [[188.0, 173.0, 342, 10], "S. aureus is an opportunistic pathogen associated with bio\ufb01lms infections, which are a"], [[167.0, 186.0, 347, 10], "common cause of pulmonary infections, ventilator-associated pneumonia, mucosal sur-"], [[167.0, 199.0, 364, 10], "faces, surgical site infections, and implanted medical devices [43]. Additionally, the absence"], [[167.0, 211.0, 351, 10], "of studies reporting on the ef\ufb01cacy of commercially used biomaterials for dental implants"], [[167.0, 224.0, 368, 10], "in patients with diseases that are chronic, systemic, or associated with changes in the micro-"], [[167.0, 236.0, 362, 10], "biome composition made the purpose of this study. The goal was to determine biomaterials"], [[167.0, 249.0, 351, 10], "that could be recommended for use in patients with CF. Our study focused on S. aureus,"], [[167.0, 261.0, 331, 10], "since S. aureus infections are considered to be a burden for the healthcare system."], [[167.0, 284.0, 107, 10], "2. Materials and Methods"], [[167.0, 297.0, 56, 10], "2.1. Reagents"], [[188.0, 313.0, 336, 10], "All reagents were purchased from Sigma Merck KGaA (Darmstadt, Germany) unless"], [[167.0, 325.0, 356, 10], "stated otherwise. Dehydrated culture media were purchased from Merck (Merck Millipore,"], [[167.0, 338.0, 89, 10], "Darmstadt, Germany)."], [[167.0, 360.0, 124, 10], "2.2. Bacterial Strain Conditions"], [[188.0, 376.0, 318, 10], "This study investigated 33 clinical strains of S. aureus obtained from the sputum"], [[167.0, 388.0, 360, 10], "samples of patients with known CF treated at the Department of Microbiology, National Tu-"], [[167.0, 401.0, 336, 10], "berculosis and Lung Diseases Research Institute (Warsaw, Poland). All study partici-"], [[166.0, 413.0, 343, 10], "pants provided informed consent to collect samples. Cultures of S. aureus were grown"], [[167.0, 426.0, 342, 10], "in Columbia Blood Agar with 5% sheep blood (bioM\u00e9rieux, Marcy-l\u2019Etoile, France) and"], [[167.0, 436.0, 343, 15], "Chapman Agar (bioM\u00e9rieux, Marcy-l\u2019Etoile, France) at 37 \u25e6C for 24\u201348 h in aerobic at-"], [[167.0, 451.0, 334, 10], "mosphere. Antimicrobial susceptibility testing was performed using the standardized"], [[167.0, 464.0, 338, 10], "disk diffusion method and gradient method with Mueller-Hinton Agar (Oxoid, France)."], [[166.0, 476.0, 351, 10], "The results were interpreted according to the European Committee of Antimicrobial Sus-"], [[167.0, 489.0, 347, 10], "ceptibility Testing (EUCAST) [44] breakpoints against the following antibiotics: cefoxitin,"], [[167.0, 501.0, 346, 10], "gentamycin, tobramycin, cipro\ufb02oxacin, levo\ufb02oxacin, erythromycin, clindamycin, tetracy-"], [[167.0, 514.0, 331, 10], "cline, trimethoprim/sulfamethoxazole, linezolid, teicoplanin, and vancomycin. All the"], [[167.0, 524.0, 336, 15], "strains were stored frozen at \u221270 \u25e6C in Lysogeny broth medium (LB) (Sigma-Aldrich,"], [[167.0, 539.0, 217, 10], "St Louis, MO, USA) with 2% glycerol prior to the study."], [[167.0, 561.0, 71, 10], "2.3. Bio\ufb01lm Assay"], [[188.0, 577.0, 311, 10], "The colorimetric assay of bio\ufb01lms with crystal violet staining was performed as"], [[166.0, 590.0, 360, 10], "previously described [45]. Fresh bacterial suspensions were prepared in LB from overnight"], [[167.0, 602.0, 358, 10], "cultures. The wells of a sterile 96-well \ufb02at-bottomed polystyrene microplate (Kartell S.p.A.,"], [[167.0, 615.0, 349, 10], "Milan, Italy) were \ufb01lled with 230 \u00b5L of LB medium with 2% glucose. The negative control"], [[166.0, 627.0, 335, 10], "wells contained only the sterile broth. Twenty microliters of overnight grown bacterial"], [[167.0, 638.0, 336, 14], "culture was adjusted to an optical density (OD) 600 of 0.1 (~107 colony-forming units"], [[166.0, 650.0, 335, 14], "(CFU)/mL\u22121) and was added into each well. After 48 h, media was aspirated and the"], [[166.0, 665.0, 347, 10], "wells were washed with sterile water. The wells were then stained with 1% crystal violet"], [[167.0, 677.0, 327, 10], "for 15 min. The unbound crystal violet stain was then removed, and the wells were"], [[166.0, 690.0, 345, 10], "washed with sterile water, air-dried, and crystal violet was dissolved by addition 200 \u00b5L"], [[167.0, 703.0, 355, 10], "of 96% ethyl alcohol. The OD of each well was measured at 584 nm wavelength using an"], [[167.0, 715.0, 359, 10], "automated Synergy HTX multi-mode reader (BioTek Instruments Inc., Winooski, VT, USA)."], [[167.0, 728.0, 362, 10], "Based on the OD, the strains were categorized as: non-bio\ufb01lm producers, weak, moderate,"], [[167.0, 740.0, 343, 10], "or strong bio\ufb01lm producers, as previously described and standardized [46,47]. All tests"], [[166.0, 753.0, 351, 10], "were performed three times in \ufb01ve replicates, the results are presented as the mean and"]], [841, 595]], [4, [[[36.0, 54.0, 77, 8], "Materials 2021, 14, 2030"], [[536.0, 54.0, 21, 8], "4 of 15"], [[167.0, 98.0, 341, 10], "standard deviations; statistical analyses were performed using StatSoft Statistica 10.0"], [[166.0, 111.0, 187, 10], "(licensed to the Medical University of Warsaw)."], [[167.0, 133.0, 146, 10], "2.4. Preparation of Biomaterial Discs"], [[188.0, 149.0, 335, 10], "Following standard dental laboratory procedures and the manufacturer\u2019s recommen-"], [[167.0, 161.0, 338, 10], "dations, we manufactured polished, circular specimens 10 mm in diameter and 2 mm"], [[167.0, 174.0, 338, 10], "in thickness from titanium alloy Ti-6Al-4V (grade 5 titanium), zirconium dioxide (yttria-"], [[167.0, 186.0, 341, 10], "stabilized tetragonal zirconia polycrystals, 3Y-TZP), and cobalt-chromium (CoCr) alloy"], [[166.0, 199.0, 353, 10], "(Duceralloy C, DeguDent GmbH, Hanau, Germany), which are commonly used in clinical"], [[166.0, 209.0, 350, 10], "practice. Original materials were obtained from Silesia Dental (S\u00b4roda S\u00b4la\u02dbska, Poland)."], [[167.0, 234.0, 144, 10], "2.4.1. Biomaterial Discs Preparation"], [[188.0, 249.0, 327, 10], "The discs were cleaned in an ultrasonic bath (POLSONIC, Warsaw, Poland) in the"], [[167.0, 260.0, 342, 14], "solution of 1% Extran\u00aeAP 15 (Merck KGaA, Darmstadt, Germany) and 99% deionized"], [[167.0, 275.0, 343, 10], "ultra-pure water (HYDROLAB, Straszyn, Poland) for 15 min, then rinsed three times in"], [[167.0, 287.0, 353, 10], "ultrapure water and ultrasonic bath for 15 min and next rinsed in ethanol 99.8% (Avantor,"], [[167.0, 300.0, 330, 10], "Gliwice, Poland) for 15 min. The discs before bio\ufb01lm formation were treated by dry-"], [[167.0, 312.0, 68, 10], "heat sterilization."], [[167.0, 335.0, 92, 10], "2.4.2. Surface Analysis"], [[188.0, 350.0, 327, 10], "The micro-level surface topography of the biomaterials Ti-6Al-4V, cobalt-chromium"], [[167.0, 363.0, 338, 10], "alloy (CoCr), and zirconia were characterized by using Multimode 5 Atomic Force Mi-"], [[167.0, 375.0, 331, 10], "croscopy instrument (Veeco, New York, NY, USA) upgraded to Multimode 8 version"], [[166.0, 386.0, 348, 14], "(Bruker). The images have been acquired in ScanAsyst\u00ae mode using dedicated silicone"], [[167.0, 400.0, 346, 10], "cantilevers. Three randomly selected regions/specimen were measured in total a mean"], [[167.0, 413.0, 347, 10], "number of 9 measurements per material were registered. AFM was used to analyze the"], [[167.0, 423.0, 367, 14], "surface roughness average of the specimens (Ra) at a micro-level (scan size: 15 \u00d7 15 \u00b5m2)."], [[167.0, 448.0, 210, 10], "2.5. Bacterial Bio\ufb01lm Formation on Biomaterial Discs"], [[188.0, 461.0, 345, 15], "Overnight cultures of S. aureus were grown on Chapman agar plates for 24 h at 37 \u25e6C."], [[166.0, 476.0, 338, 10], "A single colony of bacteria was inoculated into 10 mL of LB medium to grow statically"], [[167.0, 486.0, 364, 15], "overnight at 37 \u25e6C. The bacterial suspension (1 mL each) was then transferred to 500 mL of"], [[167.0, 499.0, 351, 15], "the appropriate medium LB and cultured in a shaker incubator at 37 \u25e6C until the bacteria"], [[167.0, 514.0, 335, 10], "grew up to the mid-exponential phase. At the next step, each inoculum was adjusted"], [[167.0, 524.0, 350, 14], "to the value 108 CFU mL\u22121. The concentration of bacteria was determined using a spec-"], [[167.0, 539.0, 351, 10], "trophotometer using an automated Synergy HTX multi-mode reader (BioTek Instruments"], [[167.0, 551.0, 341, 10], "Inc., Winooski, VT, USA). Sterile, dry-heat sterilized, titanium alloy, zirconia, and CoCr"], [[167.0, 564.0, 355, 10], "alloy disks were inserted separately into 500 mL of LB medium supplemented with 0.25%"], [[167.0, 576.0, 359, 10], "glucose in conical \ufb02asks. Then, the discs were inoculated with S. aureus to a \ufb01nal concen-"], [[167.0, 587.0, 349, 15], "tration of 105 CFU/mL\u22121 and cultured for 48 h at 37 \u25e6C in a shaker incubator at 160 rpm."], [[166.0, 601.0, 359, 10], "The disks were aseptically removed from the cultures, washed gently three times in 10 mL"], [[166.0, 614.0, 355, 12], "1\u00d7 phosphate-buffered saline buffer, 7.4 pH (PBS) (Gibco\u2122, Life Technologies, Bleiswijk,"], [[166.0, 627.0, 360, 10], "The Netherlands) to remove non-adherent cells, and then transferred to 50 mL PBS buffer."], [[167.0, 649.0, 331, 10], "2.6. Bio\ufb01lm Detachment from Surfaces and Assessment of Viability (CFU Counting)"], [[188.0, 665.0, 329, 10], "To count bacterial cells attached to the surface of the biomaterial discs after bio\ufb01lm"], [[167.0, 675.0, 371, 14], "formation, the discs were placed in 15 mL Falcon tubes (Falcon\u00ae Conical Tubes, STEMCELL,"], [[167.0, 690.0, 349, 10], "Reynosa, Mexico) containing 10 mL saline buffer and vortexed twice at 30 g for 3 min to"], [[167.0, 700.0, 353, 14], "dislodge the adherent bacteria. Ten-fold serial dilutions until 10\u22126 were prepared in saline"], [[167.0, 715.0, 360, 10], "buffer. Spread-plating (double tests) was performed on Chapman agar plates using 100 \u00b5L"], [[167.0, 725.0, 357, 15], "of the undiluted and six dilution samples. The CFU were counted after incubation at 37 \u25e6C"], [[167.0, 740.0, 33, 10], "for 24 h."]], [841, 595]], [5, [[[36.0, 54.0, 77, 8], "Materials 2021, 14, 2030"], [[536.0, 54.0, 21, 8], "5 of 15"], [[167.0, 98.0, 167, 10], "2.7. Scanning Electron Microscopy (SEM)"], [[188.0, 114.0, 359, 10], "The surfaces of the titanium alloy, zirconia, and CoCr alloy disks were examined for bacte-"], [[167.0, 126.0, 369, 10], "rial attachment using a scanning electron microscope. The disks were mounted on aluminum"], [[167.0, 139.0, 350, 10], "stubs and sputter-coated with gold-palladium. The samples were then examined using a"], [[167.0, 151.0, 356, 10], "Zeiss Merlin field-emission scanning electron microscope (Zeiss, Oberkochen, Germany)."], [[167.0, 174.0, 120, 10], "2.8. Fluorescence Microscopy"], [[188.0, 189.0, 331, 10], "The surfaces of the titanium alloy, zirconia, and CoCr alloy disks were examined for"], [[167.0, 202.0, 344, 10], "bacterial viability using \ufb02uorescence microscopy. The specimens were stained with the"], [[167.0, 214.0, 343, 10], "LIVE/DEAD kit according to the manufacturer\u2019s instructions (LIVE/DEAD\u2122 BacLight\u2122"], [[167.0, 227.0, 340, 10], "Bacterial Viability Kit, Molecular Probes, Art. No. L7012, Invitrogen, Molecular probes,"], [[167.0, 240.0, 357, 10], "Eugene, OR, USA) and examined using \ufb02uorescence microscopy (Nikon Eclipse LV 100)."], [[167.0, 262.0, 95, 10], "2.9. Statistical Analyses"], [[188.0, 278.0, 341, 10], "The results are presented as the mean with standard deviations. All data were statisti-"], [[167.0, 290.0, 347, 10], "cally analyzed from three independent experiments using the Student\u2019s t-test. Values of"], [[167.0, 302.0, 356, 10], "p < 0.05 were considered to indicate statistical signi\ufb01cance. Statistical analyses were per-"], [[167.0, 315.0, 335, 10], "formed using StatSoft Statistica 10.0 (licensed to the Medical University of Warsaw)."], [[167.0, 338.0, 43, 10], "3. Results"], [[167.0, 351.0, 125, 10], "3.1. Drug Susceptibility Pro\ufb01les"], [[188.0, 367.0, 364, 10], "The strains were resistant to cefoxitin 3/33 (9%), gentamycin 5/33 (15.2%), tobramycin 6/33"], [[166.0, 379.0, 369, 10], "(18.2%), ciprofloxacin 11/33 (33.3%), levofloxacin 5/33 (15.2%), erythromycin 22/33 (66.6%),"], [[167.0, 392.0, 356, 10], "clindamycin 18/33 (54.5%), tetracycline 4/33 (12.1%), and trimethoprim/sulfamethoxazole"], [[166.0, 404.0, 347, 10], "1/33 (3%). However, all strains were sensitive to linezolid, teicoplanin, and vancomycin."], [[167.0, 417.0, 372, 10], "Methicillin resistance was observed in 3/33 strains (9%). The antibiotic resistance phenotypes"], [[167.0, 429.0, 323, 10], "of each isolate determined using diffusion discs on agar are presented in Table 1."], [[166.0, 455.0, 304, 9], "Table 1. Antibiotic resistance phenotype of the Staphylococcus aureus clinical strains."], [[180.0, 476.0, 93, 9], "Antibiotic/N of Strains %"], [[215.0, 503.0, 29, 9], "cefoxitin"], [[209.0, 534.0, 41, 9], "gentamycin"], [[209.0, 561.0, 39, 9], "tobramycin"], [[206.0, 588.0, 44, 9], "cipro\ufb02oxacin"], [[208.0, 616.0, 42, 9], "levo\ufb02oxacin"], [[205.0, 641.0, 46, 9], "erythromycin"], [[208.0, 668.0, 42, 9], "clindamycin"], [[215.0, 696.0, 29, 9], "linezolid"], [[209.0, 722.0, 38, 9], "teikoplanin"], [[208.0, 748.0, 42, 9], "vancomycin"], [[344.0, 476.0, 35, 9], "Sensitive"], [[358.0, 492.0, 9, 9], "30"], [[355.0, 502.0, 16, 9], "91.0"], [[325.0, 514.0, 68, 9], "Phenotype MSSA *"], [[358.0, 529.0, 9, 9], "28"], [[355.0, 540.0, 16, 9], "84.8"], [[358.0, 556.0, 9, 9], "27"], [[355.0, 567.0, 16, 9], "81.8"], [[358.0, 583.0, 9, 9], "22"], [[355.0, 594.0, 16, 9], "66.7"], [[358.0, 609.0, 9, 9], "28"], [[355.0, 620.0, 16, 9], "84.8"], [[358.0, 636.0, 8, 9], "11"], [[355.0, 647.0, 16, 9], "33.3"], [[358.0, 663.0, 9, 9], "15"], [[355.0, 674.0, 16, 9], "45.5"], [[358.0, 689.0, 9, 9], "33"], [[356.0, 700.0, 13, 9], "100"], [[358.0, 716.0, 9, 9], "33"], [[356.0, 727.0, 13, 9], "100"], [[358.0, 743.0, 9, 9], "33"], [[356.0, 754.0, 13, 9], "100"], [[472.0, 476.0, 42, 9], "Resistance"], [[491.0, 492.0, 4, 9], "3"], [[488.0, 502.0, 11, 9], "9.0"], [[453.0, 514.0, 72, 9], "Phenotype MRSA **"], [[491.0, 529.0, 4, 9], "5"], [[486.0, 540.0, 16, 9], "15.2"], [[491.0, 556.0, 4, 9], "6"], [[486.0, 567.0, 16, 9], "18.2"], [[489.0, 583.0, 8, 9], "11"], [[486.0, 594.0, 16, 9], "33.3"], [[491.0, 609.0, 4, 9], "5"], [[486.0, 620.0, 16, 9], "15.2"], [[489.0, 636.0, 9, 9], "22"], [[486.0, 647.0, 16, 9], "66.7"], [[489.0, 663.0, 9, 9], "18"], [[486.0, 674.0, 16, 9], "54.5"], [[491.0, 696.0, 4, 9], "0"], [[491.0, 723.0, 4, 9], "0"], [[491.0, 749.0, 4, 9], "0"]], [841, 595]], [6, [[[36.0, 54.0, 77, 8], "Materials 2021, 14, 2030"], [[193.0, 13.0, 64, 16], "vancomycin"], [[364.0, 6.0, 10, 13], "33"], [[511.0, 14.0, 5, 13], "0"], [[362.0, 21.0, 15, 13], "100"], [[195.0, 43.0, 61, 16], "tetracycline"], [[364.0, 37.0, 10, 13], "29"], [[360.0, 51.0, 18, 13], "87.9"], [[511.0, 37.0, 5, 13], "4"], [[504.0, 51.0, 18, 13], "12.1"], [[536.0, 54.0, 21, 8], "6 of 15"], [[154.0, 67.0, 142, 16], "trimethoprim/sulfamethox"], [[364.0, 67.0, 10, 13], "32"], [[511.0, 67.0, 5, 13], "1"], [[212.0, 83.0, 28, 16], "azole"], [[360.0, 83.0, 18, 13], "97.0"], [[507.0, 83.0, 13, 13], "3.0"], [[154.0, 98.0, 429, 18], "* MTSaSbAle\u20141.mCeontht.icillin-sensitive Staphylococcus aureus. ** MRSA\u2014methicillin-resistant Staphylo-"], [[154.0, 112.0, 149, 16], "coccusAanutirbeiuost.ic/N of Strains %"], [[344.0, 119.0, 35, 9], "Sensitive"], [[472.0, 119.0, 42, 9], "Resistance"], [[154.0, 135.0, 314, 18], "3.2. ClinicaltSettrraaciyncslinweith Different Capacity fo2r9 Biofilm Formation"], [[491.0, 135.0, 4, 9], "4"], [[355.0, 146.0, 16, 9], "87.9"], [[486.0, 146.0, 16, 9], "12.1"], [[177.0, 156.0, 381, 16], "We investigated biofilm formation of3323 clinical strains of S. aureu1s isolated from the"], [[154.0, 167.0, 507, 18], "sputturimmetohfoppraimti/esnutlsfamweitthhoxCaFzo.leTo confirm t9h7e.0ability of the given S. au3r.e0us strains isolated"], [[154.0, 184.0, 684, 17], "fro*mMSsSpAu\u2014tmuemthictiollinfo-sremnsitbivieoSftialpmhysl,ocwocecuus asuerdeuas.n**iMnRvSAit\u2014romteethsitc,illains-rpesrisetavnitoSutasplhyyldoceoscccursibauerdeu.sT. he ca-"], [[154.0, 198.0, 377, 13], "pacity to form a biofilm after 48 h of incubation varied among the clinical strains of S."], [[154.0, 209.0, 614, 19], "aur3e.u2.s.CBliansiceadl SotnratihnseiwriOthDD,iftfhereensttrCaainpascwityefroer cBaiote\ufb01glmorFiozremdaatisonstrong, moderate, weak, or non-"], [[154.0, 224.0, 651, 19], "biofilmWperoindvuecsteirgsa.teOdfbtiho\ufb01elm33focrlminaictiaolnsotfra3i3ncslienvicaallusatrtaeidnsfoofr Sa.baiulriteyusoisfoblaitoefdilmfromforthmeation,"], [[154.0, 237.0, 701, 19], "neasprluytuamll ostfrpaaintiesn(t3s0w/3it3h; C90F..9T%o c)own\ufb01errme cthaepaabbilleityofoffothremgiinvgenbSio. afuilrmeuss s(Ftriaginusreiso1l)a.tAedsfsrohmown in"], [[154.0, 250.0, 677, 19], "Figsupruetu1m, 8t/o33fosrmtrabinios\ufb01(lm24s.,2w%e) uwseedreancaitnegviotrroizteedst,aasswpreeavkio, u2s0l/y33de(s6c0r.i6b%ed). aTshme coadpearcaittye, and"], [[167.0, 262.0, 342, 10], "to form a bio\ufb01lm after 48 h of incubation varied among the clinical strains of S. aureus."], [[154.0, 269.0, 703, 16], "2/3B3a(s6e.d1%on) tahseisrtrOoDn,gthbeiosftrilaminspwroedreuccaetresg.oSrtizueddeanst\u2019sstrto-ntegs,tmsohdoewraetde, swigeankif,iocrannot nd-ibfifoe\ufb01relmnces in"], [[154.0, 283.0, 633, 16], "theparomdouucenrts.oOf bf itohfeil3m3 cplirnoidcaulcsetrdaibnys tehveaslueagterdoufoprsaobfilsittyraoinf bsi(op\ufb01<lm0.f0o5r,mpa<tio0n.0, 0n1e)a.rly all"], [[167.0, 297.0, 648, 16], "strOaiunst (o30f/t3h3e; 930.39%st)rwaienrse ctaepsatebdle, oof nfoermminogdbelio\ufb01stlrmasin(Foigfurme e1t)h. Aicsilslihno-wrensiisntaFnigturSe. 1a,ureus"], [[154.0, 311.0, 700, 13], "(M8R/S3A3 )s,trSa.inasu(r2e4u.2s%st)rwaienrencuatmegboerriz3ed\uf0aeaswwheicahk, w20a/s33ob(6s0e.r6v%e)dastombodeerreasteis, taanndt 2t/o3c3e(f6o.1x%it)in, to-"], [[154.0, 325.0, 688, 19], "braams sytcroinn,g cbipo\ufb01rolmflopxraocdiunc,erlse.vSotfuldoexnatc\u2019isnt,-teesrtysthhorwomedysciignn,i\ufb01acnadnt dcliifnfedreanmceyscinn thaenadmpouonsstessed"], [[154.0, 337.0, 532, 19], "stroofnbgiob\ufb01iolmfilpmro-fdourcmedinbgyctahpesaecigtryo,uwpsasofcshtorasienns (fpor<f0u.0rt5h, epr<in0.v0e0s1t)i.gation."], [[68.0, 368.0, 24, 15], "3.32 *"], [[68.0, 395.0, 11, 11], "2.8"], [[68.0, 408.0, 11, 11], "2.6"], [[68.0, 422.0, 11, 11], "2.4"], [[357.0, 386.0, 132, 11], "Strong biofilm producer N=2 / 6.1%"], [[357.0, 403.0, 154, 11], "Moderate biofilm producer N=20 / 60.6%"], [[357.0, 419.0, 133, 11], "Weak biofilm producer N=8 / 24.2%"], [[68.0, 435.0, 11, 11], "2.2"], [[357.0, 436.0, 123, 11], "Non biofilm producer N=3 / 9.1%"], [[76.0, 448.0, 5, 11], "2"], [[68.0, 462.0, 11, 11], "1.8"], [[68.0, 475.0, 11, 11], "1.6"], [[68.0, 488.0, 11, 11], "1.4"], [[68.0, 502.0, 20, 19], "1.2 *"], [[76.0, 515.0, 5, 11], "1"], [[68.0, 528.0, 11, 11], "0.8"], [[134.0, 525.0, 6, 15], "*"], [[68.0, 542.0, 11, 11], "0.6"], [[68.0, 555.0, 11, 11], "0.4"], [[108.0, 549.0, 6, 15], "*"], [[68.0, 568.0, 11, 11], "0.2"], [[76.0, 582.0, 5, 11], "0"], [[94.0, 593.0, 302, 10], "1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33"], [[121.0, 606.0, 6, 10], "\uf0ae"], [[284.0, 608.0, 57, 11], "Isolate number"], [[34.0, 634.0, 837, 16], "FigurFeig1u. rBei1o.fiBlmio\ufb01-flmor-mfoirnmgincgacpaapcaictyityooffSS.. aauurreeuussclcilniniciaclasltrsatirnasi.nTsh. eTshtreaisntsraoifnSs. oaufrSeu.sawureeruesaswseesrseedafsosresthseeidr afboirlittyhetoirfoarbmility to"], [[34.0, 647.0, 851, 16], "form aabbioio\ufb01flmilmanadnadccaocrdcoinrgdlyincglalyssic\ufb01leadssaisfisetdronasg,smtroodnegra, tme, owdeearka, taen,dwneoank-p, raondducnerosn. R-persuoldtsuacreerse.xpRreesssueldtsasartheeemxpearnesvsaeldueas the"], [[34.0, 659.0, 833, 16], "mean\u00b1vastlauned\u00b1arsdtadnevdiaartidondseovfitahteiomnesaonfotfhaet lmeaesatn5 ionfdaetpelenadsetn5t eixnpdeerpimeenndtesnpterefxoprmereidmienntrtsippliecartfeo.rTmoecdlasinsiftyritphleicsatrtaei.nTs ointcolassify"], [[57.0, 676.0, 435, 9], "groups that showed signi\ufb01cant differences, statistical analysis was performed using Student\u2019s t-test (* p < 0.05). The isolate"], [[57.0, 688.0, 205, 9], "number 3 that formed high levels of bio\ufb01lm is indicated ( )."], [[188.0, 710.0, 347, 10], "Out of the 33 strains tested, one model strain of methicillin-resistant S. aureus (MRSA),"], [[166.0, 723.0, 343, 10], "S. aureus strain number 3 which was observed to be resistant to cefoxitin, tobramycin,"], [[167.0, 735.0, 350, 10], "cipro\ufb02oxacin, levo\ufb02oxacin, erythromycin, and clindamycin and possessed strong bio\ufb01lm-"], [[167.0, 748.0, 214, 10], "forming capacity, was chosen for further investigation."]], [841, 595]], [7, [[[18.0, 13.0, 539, 15], "the strains into groups that showed significant differences, statistical analysis was performed using Student\u2019s t-"], [[18.0, 27.0, 376, 15], "0.05). The isolate number 3 that formed high levels of biofilm is indicated (\uf0ae)."], [[36.0, 54.0, 77, 8], "Materials 2021, 14, 2030"], [[160.0, 58.0, 150, 16], "3.3. Biofilm Formation in CFU"], [[536.0, 54.0, 21, 8], "7 of 15"], [[188.0, 79.0, 380, 16], "The number of microbes adherent on biomaterial discs varied dependin"], [[160.0, 96.0, 504, 16], "te3r.3i.aBl iuo\ufb01slmedF.orSm.aatiuonreinuCs FgUrowth was significantly lower (p < 0.05) on the surface"], [[160.0, 112.0, 655, 19], "compTahreendumtobetrhoaftmoincroobtehseardhmeraetnetroianlbsi.oBmiaotefriliaml ddisecsnvsiatryiedfodrempeenddinognotnhteheCoCr a"], [[160.0, 126.0, 722, 19], "wmaastetrhiael uhsiegd.hSe.satu,rewusigthrowsitghnwiafsicsaignnti\ufb01lycanhtilgy hloewrerlo(pg<C0.F05U) o/mn tLhe\u22121suvrafalcueseosf, zciorcmonpiaared to"], [[167.0, 139.0, 344, 10], "compared to that on other materials. Bio\ufb01lm density formed on the CoCr alloy surfaces"], [[160.0, 146.0, 689, 19], "owthaesrtheevhaiglhueastt,ewditmh saigtenri\ufb01iacalnstl(yph<igh0e.0r 5lo)g. CBFaUc/temrLia\u2212l1 gvarlouwes,thcomonpaTreid-6toAthl-o4sVe osnurfaces"], [[160.0, 162.0, 678, 19], "cathnetloythleorwevearlu(apte<d 0m.0at5e)ritahlsa(np o<n0.C05o).CBraactlelroiayl sgurorwfathceosn, Tbiu-6tAsl-i4gVnisfuircfacnetslywahsigher ("], [[160.0, 176.0, 701, 19], "thsiegngi\ufb01rcoawntltyhloownerz(ipr<co0.n05ia) thsaunrofancCeosC.rFailglouy rseur2facsehs,obwutssitghnie\ufb01ctaonttalyl hbigiohefril(mp <f0o.0r5m) ation"], [[167.0, 189.0, 347, 10], "than the growth on zirconia surfaces. Figure 2 shows the total bio\ufb01lm formation (in CFU"], [[160.0, 196.0, 480, 19], "C(FloUg C/mFUL/\u2212m1)L)\u2212o1n)) othnethseusurfrfaacceessoof fdidffiefrfeenrt ebniotmbaitoermialas.terials."], [[160.0, 478.0, 700, 18], "FiFgiguurree 22. .BBioi\ufb01olfmilfmormfoartimona(tiniocnolo(inny-cfoorlmoinnyg -ufnoirtsm(lionggCFuUn/imtsL(-l1o))gonCtFhUe s/umrfaLc-e1s))oof dniftfehreensturfaces"], [[160.0, 490.0, 701, 18], "biboiommaatteerriaialsl.sE.rErorrrboarrsbraeprsrerseenptrtehesepnootltehdestpanodoalredddesvtiaantiodnasrodf tdheevmieaatnio(nn=s 5o)f. Tthheelemveelaonf (n = 5)"], [[167.0, 503.0, 293, 9], "signi\ufb01cance was preset at * p = 0.05. The mean and standard deviation are shown."], [[160.0, 511.0, 395, 15], "significance was preset at * p = 0.05. The mean and standard deviation are shown."], [[167.0, 523.0, 160, 10], "3.4. Surface Topography Characteristics"], [[160.0, 538.0, 524, 19], "3.4. SRuerpfraecseenTtaotpivoegbraaspelhinye CSEhMariamcatgeersisotficthse different biomaterial specimens are shown"], [[167.0, 551.0, 360, 10], "in Figure 3. In all cases, the examined discs exhibited a smooth surface topography, with a"], [[167.0, 563.0, 680, 19], "few \ufb01Rneepproelissheinngtamtiavrkes hboamsoegleinneeouSslEy Mdistriimbuategdeosveor fthethsuerfadceif. fSeinrceenatll sbpieocmimaentesrial sp"], [[160.0, 576.0, 687, 19], "shwoerwe npoilnishFeidguusrieng3a. Isniliacollnccaasrbeisd,etphaepeerxtaomacihnieevdedaihsicgshleyxghloibssiyte\ufb01dniashs,mthoe odtishkssurface"], [[167.0, 589.0, 222, 10], "displayed similar surface topography upon examination."], [[160.0, 596.0, 683, 19], "with AaFMfewimafgienseexphioblitiesdhdinifgferemncaerskins shurofamceotgopeongeraopuhsylydude tiostvrairbiouutsebdiomovateerriatlhs e surf"], [[160.0, 613.0, 696, 19], "sp(Feigcuimre e3nB,sC)w. Peorleishpeodlizsirhceondiuumsisnugrfaacesi(bli)csohnowceadrbthide elowpeaspt erorutgohnaecshs iveavlueesaohf ighly g"], [[160.0, 626.0, 653, 21], "thRea d(2i3s.8k\u00b1s d9.i3s7pnlmay),ewdhsiliemCiolCarr asluloryfashcoewteodptohegrhaigphhesyt Ruap(o16n5.e2x\u00b1am79.i8n0antmio)nv.alue."], [[166.0, 638.0, 350, 12], "The titanium surface showed moderate values Ra (36.2 \u00b1 15.25 nm). The Ti-6Al-4V and"], [[167.0, 646.0, 674, 19], "zircoAniuFmMsuimrfaacegsehsaedxphariabllietlegdrodoivfefsearleonngcethseipnosliushrifnagcdeirteoctpioong(rFaigpuhrey3Bd(ua,eb)t).o various"], [[160.0, 663.0, 682, 19], "(FiguTrhee3mBe,aCn)v.aPluoesliosfhseudrfazceirrcoounghiunemss fsour rthfae cbeiom(ba)tesrhiaolswaredprethseentleodwineTsatblreo2u. ghness"], [[160.0, 679.0, 395, 16], "(23.8 \u00b1 9.37 nm), while CoCr alloy showed the highest Ra (165.2 \u00b1 79.80 nm"], [[166.0, 689.0, 210, 9], "Table 2. Surface roughness (Ra) of the tested biomaterials."], [[160.0, 696.0, 403, 16], "titanium surface showed moderate values Ra (36.2 \u00b1 15.25 nm). The Ti-6Al-4"], [[160.0, 710.0, 587, 19], "nium suCrasftaincgeTsehchandiqupeas ranadllAelllogyrsooves along thRea p(noml)iMsheainn g\u00b1 SdDirne=ct9ion (Figure 3B,"], [[188.0, 726.0, 535, 24], "The meZairncoTvni-ia6uAlmul-de4iVsoxoidfesurface roughness for th326e3.2.8b\u00b1\u00b1io195m..3275aterials are presente"], [[243.0, 748.0, 37, 9], "CoCr alloy"], [[435.0, 748.0, 50, 10], "165.2 \u00b1 79.80"], [[160.0, 761.0, 282, 15], "Table 2. Surface roughness (Ra) of the tested biomaterials."], [[210.0, 786.0, 170, 16], "Casting Techniques and Alloys"], [[275.0, 805.0, 52, 16], "Ti-6Al-4V"], [[249.0, 822.0, 100, 16], "Zirconium dioxide"], [[485.0, 786.0, 104, 16], "Ra (nm) Mean \u00b1SD"], [[526.0, 805.0, 60, 16], "36.2 \u00b1 15.25"], [[529.0, 822.0, 54, 16], "23.8 \u00b1 9.37"]], [841, 595]], [8, [[[36.0, 54.0, 153, 16], "MMaatteerriiaallss 22002211,, 1144,, 22003300"], [[536.0, 54.0, 41, 16], "88 ooff 1156"], [[57.0, 584.0, 427, 9], "Figure 3. (A) Scanning electron microscopy (SEM) micrographs. Representative SEM images of the different biomaterial"], [[57.0, 595.0, 843, 16], "sFpigeucirme e3n. s(A. I)nSacallncnaisnegs,etlhecetreoxnammiincerdosdcoispkys (gSeEnMer)amllyicerxohgribaiptheds. aRsemproeosethntsautirvfaecSeEtMopiomgraagpehs yo,fwthitehdsioffmereen\ufb01tnbeipomolaistheriniagl"], [[57.0, 606.0, 814, 16], "mspaerckims ehnosm. Iongeanllecoausselsy, tdhiesterixbaumteindeodvdeirskthsegesnuerfraaclley. e(xah),ibTitie-6dAal-s4mVo(ogtrhadsuer5fatcietatnoipuomgr);ap(bh)y,ziwrcitohnisuommedfiionxeidpeol(iysthtirniag-"], [[57.0, 618.0, 863, 16], "smtaabrikliszhedomteotrgaegnoenoaulszliyrcdoinstiaripbuoltyecdryosvtearlst-h3eY-sTuZrfPa)c; e(c. )(ac)o,bTail-t6-cAhlr-o4mVi(ugmra(dCeo5Ctri)taanlliouym(D); u(bce)rzailrlcooynCiu).mOdriigoixniadlem(yagttnriia\ufb01-csattaiboin-"], [[57.0, 629.0, 847, 16], "\u00d7liz1e0d00te(tSrcaagloenbaalrz=irc1o0n\u00b5iamp).o(lyBc)rAysFtMalsm-3iYc-rToZgrPa)p; h(cs) schoobwaltt-hchersoumrfiaucme t(oCpooCgrr)apalhloyyo(fDthuecetreasltleodybCio).mOartiegriinaalsl (ma)a,gTni-if6iAcalt-i4oVn;"], [[57.0, 641.0, 472, 13], "\u00d71000 (Scale bar = 10 \u03bcm). (B) AFM micrographs show the surface topography of the tested biomaterials (a), Ti-6Al-4V;"], [[56.0, 648.0, 829, 18], "((bb)) zziirrccoonniiuumm ddiiooxxiiddee;; ((cc))ccoobbaalltt--cchhrroommiuiumm(C(CooCCr)r)aallloloyy. .CCalaiblirbartaetdedtoto22252\u03bc5 m\u00b5m2 s2amsapmlepsluersfuacrefa. c(eC.) (3CD) a3tDomatiocmfoirccefomrcie-"], [[57.0, 661.0, 702, 18], "mcroicsrcoospcoyp(yAF(AMF)Mim) iamgeasgefosrfo(ar)(aT)i-T6iA-6lA-4lV-4;V(b; ()bz)irzciorcnoiunmiumdidoxioidxied; e(c; )(cc)ocboablta-lcth-crhormomiuimum(C(oCCorC)ra)llaollyo.y."], [[166.0, 688.0, 495, 16], "33..55.. BBiioof\ufb01illmm FFoorrmmaattiioonn bbyy SS.. aauurreeuuss oonn TThhrreeee DDiiffffeerreenntt BBiioommaatteerriiaallss"], [[187.0, 704.0, 621, 16], "OOnnee ooff tthhee ppaarraammeetteerrss tthhaatt aaffffeecctt bbiioof\ufb01illmm ffoorrmmaattiioonn iiss tthhee ssuurrffaaccee pprrooppeerrttiieess ooff tthhee"], [[166.0, 716.0, 660, 16], "bbiioommaatteerriiaall.. TThhee bbiioo\ufb01fillmm pprroodduuccttiioonnaabbiliiltiytyooffoonneeclcilniniciaclaSl .Sa.uarueruesusstrsatrinain(st(rsatrinainnunmubmebr e3r)"], [[166.0, 729.0, 653, 16], "3w)aws taesstteedstuedsinugsitnhgretehdreifefedreifnfterbeinomt baitoemriaaltse.rBiaiols\ufb01. lBmios ffiolmrmsefdoromneadll othne atellsttehde btieosmteadtebriioa-l"], [[166.0, 742.0, 632, 16], "mspaetceirmiaelnsps.ecSimEMensim. SaEgMesimofatghees obfioth\ufb01elmbiocufilltmurceulatfuterer ainftceurbinactiuobnatfioorn4f8orh48arheasrheoswhonwinn"], [[166.0, 755.0, 659, 16], "iFnigFuigreur4eA4.AF.igFuigruer4eB4Bshsohwows sthtehe\ufb02fuluoroersecsecnencecemmicicroroscscooppyyimimaaggeessoobbttaaiinneeddaafftteerr ssttaaiinniinngg"], [[166.0, 768.0, 658, 16], "tthhee bbiioof\ufb01illmmss ffoorrmmeedd oonn TTii--66AAll--44VV,,zziirrccoonniiaa,,aannddCCooCCrraallllooyyssuurrffaacceesswwiitthhtthheeLLIIVVEE//DDEEAADD"]], [841, 595]], [9, [[[36.0, 54.0, 77, 8], "Materials 2021, 14, 2030"], [[36.0, 96.0, 81, 11], "Materials 2021, 14, 2030"], [[536.0, 54.0, 21, 8], "9 of 15"], [[167.0, 96.0, 372, 15], "BacLight kit. Live bacteria cells in bio\ufb01lm \ufb02uoresce bright green, whereas dead cells10wofit1h6"], [[167.0, 111.0, 192, 10], "compromised membranes \ufb02uoresce red-orange."], [[57.0, 728.0, 829, 18], "FFiigguurree 44.. ((AA))SSccaannnnininggeleelcetcrtoronnmmicircorsocsocpoypyimimagaegse(sa\u2013(ac\u2013)co)fobfiobfiiolm\ufb01lsmosnodnifdfeirfefenrtebnitobmioamteraitaelrsi.a(las)., (Tai)-,6ATil--64AVl-(4gVrad(ger5adtieta5-"], [[57.0, 741.0, 833, 18], "tnitiuanmiu);m(b);) (zbir)czoinrciounmiudmiodxidoex;id(ce); c(co)bcaoltb-achltr-ochmrioummiu(mCo(CCro)Carll)oayll(oDyu(cDeuraclelorayllCoy). C(B).) (FBlu) Forluesocreenscenmceicmroisccropscyoipmyaigmeasg(aes\u2013"], [[56.0, 753.0, 806, 13], "(ca)\u2013, ca)f,tearftsetrasintaiinnginwgiwthitahLaILVIEV/ED/EDAEDABDaBcLacigLhigthktitkoitnodnidffiefrfernetnbtiboimomataetreirailasl.s(.a()aT) Ti-i6-6AAl-l4-4VV; ;(b(b))zziirrccoonniiuummddiiooxxiidde; (c) CoCr"], [[57.0, 765.0, 374, 13], "alloy (Duceralloy C). Original magnnii\ufb01ficcaattiioonn \u00d7\u00d71100,,000000((SSccaalleebbaarr==11\u03bc\u00b5mm)).."]], [841, 595]]]